Documente Academic
Documente Profesional
Documente Cultură
Tintoiu FESC
Centrul de Cardiologie al Armatei
Universitatea Titu Maiorescu
Outline
Outline
Definitions ,Etiology,Pathophisiology
Definitions ,Etiology,Pathophisiology
Drug thera!
Drug thera!
(ACE-I, AR, !eta!loc"ers,
(ACE-I, AR, !eta!loc"ers,
aldosterone !loc"ade, digo#in$
aldosterone !loc"ade, digo#in$
Device thera!
Device thera!
Future directions
Future directions
Clinical syndrome that can result
Clinical syndrome that can result
from any structural or functional
from any structural or functional
cardiac disorder that impairs the
cardiac disorder that impairs the
ability of the ventricle to fill with
ability of the ventricle to fill with
or eject blood
or eject blood
Definition
Definition
Can %e
Can %e
s!stolic or diastolic
s!stolic or diastolic
#
#
left' or
left' or
right'sided#
right'sided#
acute or chronic
acute or chronic
"EA(T FAI)U(E
"EA(T FAI)U(E
Modern clinical definition
Modern clinical definition
ESC guideline ESC guideline
Typical symptoms
and signs of
heart failure
Cardiac dysfunction
confirmed
(ECG, imaging modalities)
Neurohumoral
aktivation confirmed
(BNP)
esponse to
heart failure
treatment
A normal heart pumps blood in a smooth and synchronized way. A normal heart pumps blood in a smooth and synchronized way.
Heart Failure Heart
Heart Failure Heart
A heart failure heart has a reduced ability to pump blood. A heart failure heart has a reduced ability to pump blood.
Adatation in heart failure
Adatation in heart failure
*Comensator! Mechanism+
*Comensator! Mechanism+
&entricular remodelling
&entricular remodelling
LV mass, size, shape is altered
Etiology
Etiology
It can !e caused !y ,
It can !e caused !y ,
-
-
Inappropriate -or" load
Inappropriate -or" load ( (%olume or pressure %olume or pressure
o%erload$ o%erload$
-
-
Restricted filling
Restricted filling
-
-
.yocyte loss
.yocyte loss
ETIO)O,IES OF "EA(T FAI)U(E ETIO)O,IES OF "EA(T FAI)U(E
Deressed E-ection Fraction *./01+ Deressed E-ection Fraction *./01+
Coronar! arter! disease Coronar! arter! disease 2onischemic dilated cardiom!oath! 2onischemic dilated cardiom!oath!
M!ocardial infarction M!ocardial infarction Familial3genetic disorders Familial3genetic disorders
M!ocardial ischemia M!ocardial ischemia Infiltrative disorders Infiltrative disorders
Chronic ressure overload Chronic ressure overload To&ic3drug'induced damage To&ic3drug'induced damage
"!ertension "!ertension Meta%olic disorders Meta%olic disorders
O%structive valvular disease O%structive valvular disease 4iral 4iral
Chronic volume overload Chronic volume overload Chagas5 disease Chagas5 disease
(egurgitant valvular disease (egurgitant valvular disease Disorders of rate and rh!thm Disorders of rate and rh!thm
Intracardiac *left'to'right+ shunting Intracardiac *left'to'right+ shunting Chronic %rad!arrh!thmias Chronic %rad!arrh!thmias
E&tracardiac shunting E&tracardiac shunting Chronic tach!arrh!thmias Chronic tach!arrh!thmias
Heart Failure,
Heart Failure,
Etiologies
Etiologies
Other Other 61 61
Alcohol Alcohol /1 /1
Fo# /F, Co-ie .R, 0ood DA, et al+ Coronary artery disease as the cause of incident heart Fo# /F, Co-ie .R, 0ood DA, et al+ Coronary artery disease as the cause of incident heart
failure in the population+ failure in the population+ Eur Heart J Eur Heart J+ 1223)11,114-156+ + 1223)11,114-156+
!
!
"olume overload#
"olume overload# egurgitate valve egurgitate valve
$igh output status $igh output status
!
!
Pressure overload#
Pressure overload# %ystemic hypertension %ystemic hypertension
&utflo' o(struction)*% &utflo' o(struction)*%
!
!
+oss of muscles#
+oss of muscles# Post ,-, Chronic ischemia Post ,-, Chronic ischemia
Connective tissue diseases Connective tissue diseases
-nfection, Poisons -nfection, Poisons
(alcohol,co(alt,.o/oru(icin (alcohol,co(alt,.o/oru(icin) )
!
!
estricted 0illing#
estricted 0illing# Pericardial diseases, Pericardial diseases,
estrictive estrictive cardiomyopathy cardiomyopathy
Tachyarrhythmia Tachyarrhythmia
Causes of C$0
Adapted from Cohn JN. N Engl J Med. 1996;335:9!"9#.
Pathologic
remodeling
+o' e1ection
fraction
.eath
%ymptoms#
.yspnea
0atigue
Edema
Chronic
heart
failure
$
Neurohormonal
stimulation
$ ,yocardial
to/icity
%udden
.eath
Pump
failure
Coronary artery
disease
$ypertension
Cardiomyopathy
"alvular disease
,yocardial
in1ury
Pathologic Progression of C4 Disease
Pathologic Progression of C4 Disease
.ia(etes
Pathophysiology
Hemodynamic changes
Hemodynamic changes
7eurohormonal changes
7eurohormonal changes
Cellular changes
Cellular changes
"emod!namic changes
"emod!namic changes
Changes in Ca
Changes in Ca
+2 +2
handling.
handling.
Changes in adrenergic receptors:
Changes in adrenergic receptors:
8 8
'light 'light in in 9 9
3 3
receptors receptors
8 8 : :
3 3
receptors desensiti;ation receptors desensiti;ation follo-ed !y do-n regulation follo-ed !y do-n regulation
D!snea
D!snea
Orthonea
Orthonea
Edema
Edema
Cough
Cough
)iver engorgement
)iver engorgement
&T$&PNE*
J%&%lar Veno%s 'istention J%&%lar Veno%s 'istention
not dire(tl) related to LV*+ not dire(tl) related to LV*+
E2G
Old MI or recent MI
Old MI or recent MI
Arrh!thmia
Arrh!thmia
Some forms of Cardiom!oath! are tach!cardia
Some forms of Cardiom!oath! are tach!cardia
related
related
);;;
);;;
>
>
may help in management
may help in management
"eart ;loc?
"eart ;loc?
hythm pro(lems leading to C$0
Chest X-ray
Chest X-ray
Pleural effusion
Pleural effusion
Chest 34ray
>oo" for Heart si;e
Pulmonary %ascular mar"ings
C?PD, pneumonia, Pneumothora#, -idened mediastinum
Pleural effusions
Echocardiogram
Function of %oth ventricles
Function of %oth ventricles
@all motion a%normalit! that ma! signif! CAD
@all motion a%normalit! that ma! signif! CAD
4alvular a%normalit!
4alvular a%normalit!
Intra'cardiac shunts
Intra'cardiac shunts
Pericardial effusion
Pericardial effusion
(estrictive ericarditis
(estrictive ericarditis
Pulmonar! h!ertension
Pulmonar! h!ertension
DC.
DC.
HC., H?C.
HC., H?C.
Restricti%e C.P
Restricti%e C.P
Cardiac Catheteri5ation
Coronar! arter! disease
Coronar! arter! disease
Dilated ventricle
Dilated ventricle
"!erd!namic small ventricle
"!erd!namic small ventricle
@all motion a%normalit! that ma! signif! CAD
@all motion a%normalit! that ma! signif! CAD
4alvular a%normalit!
4alvular a%normalit!
Intra'cardiac shunts
Intra'cardiac shunts
Pulmonar! h!ertension
Pulmonar! h!ertension
+a( Tests
Anemia
Anemia
"!erth!roid
"!erth!roid
Chronic renal insuffienc!
Chronic renal insuffienc!
Electrol!te a%normalit!'2a# A# Mag# Calcium
Electrol!te a%normalit!'2a# A# Mag# Calcium
Pre'renal aBotemia
Pre'renal aBotemia
"emochromatosis
"emochromatosis
;2P
;2P
TS"
TS"
"gA7c
"gA7c
Classif!ing "eart
Classif!ing "eart
Failure:
Failure:
Terminolog! and
Terminolog! and
Staging
Staging
+ +
A Ae! Indicator for Diagnosing "eart
A Ae! Indicator for Diagnosing "eart
Failure
Failure
E-ection Fraction *EF+
E-ection Fraction *EF+
Hypertension Hypertension
EF A B2C EF A B2C
Acute
Acute
Chronic
Chronic
Acute Decomensated
Acute Decomensated
Signs include:
Signs include:
(achycardia (achycardia
Confusion Confusion
70&8*. 0*-+9E: (+o' Cardiac &utput)#
.ecreased perfusion of the (rain (confusion)6
kidneys (impaired renal function),
skin (cyanosis) etc6
7
7B*C28*.
0*-+9E:
#
-ncreased
pulmonary
venous pressure,
pulmonary edema
Chronic "eart Failure
Chronic "eart Failure
Ma?ing an accurate diagnosis of heart failure and determining its Ma?ing an accurate diagnosis of heart failure and determining its
cause can %e difficult cause can %e difficult
Clinical diagnosis is confirmed to !e accurate in appro#imately half of Clinical diagnosis is confirmed to !e accurate in appro#imately half of
cases -hen in%estigated !y echocardiography+ cases -hen in%estigated !y echocardiography+
The li?elihood of heart failure in the resence of suggestive s!mtoms The li?elihood of heart failure in the resence of suggestive s!mtoms
and signs is increased if and signs is increased if there is a history of myocardial infarction (.I$ or there is a history of myocardial infarction (.I$ or
angina, an a!normal ECG, or a chest H-ray sho-ing pulmonary congestion angina, an a!normal ECG, or a chest H-ray sho-ing pulmonary congestion
or cardiomegaly+ or cardiomegaly+
'hortness of !reath on e#ertion (sensiti%ity 66C, specificity E1C$ 'hortness of !reath on e#ertion (sensiti%ity 66C, specificity E1C$
Decreased e#ercise tolerance (often simply *fatigue*$ Decreased e#ercise tolerance (often simply *fatigue*$
Paro#ysmal nocturnal dyspnoea (sensiti%ity 55C, specificity I6C$ Paro#ysmal nocturnal dyspnoea (sensiti%ity 55C, specificity I6C$
?rthopnoea (sensiti%ity 13C, specificity 43C$ ?rthopnoea (sensiti%ity 13C, specificity 43C$
An"le s-elling (sensiti%ity 15C, specificity 42C$ An"le s-elling (sensiti%ity 15C, specificity 42C$
Acute vs. Chronic
Acute vs. Chronic
Acute
Acute
Can emergenc! situation
Can emergenc! situation
in -hich a
in -hich a
patient -as completely asymptomatic !efore
patient -as completely asymptomatic !efore
the onset of heart failure) seen in acute heart
the onset of heart failure) seen in acute heart
inFury such as .I
inFury such as .I
Chronic
Chronic
Jlong-term syndrome
Jlong-term syndrome
in -hich a
in -hich a
patient e#hi!its symptoms o%er a long period
patient e#hi!its symptoms o%er a long period
of time, usually as a result of a pree#isting
of time, usually as a result of a pree#isting
cardiac condition
cardiac condition
T!es
T!es
ystolic
ystolic
*uming ro%lem
*uming ro%lem
$Jina!ility of the heart to
$Jina!ility of the heart to
contract to pro%ide enough !lood flo- for-ard
contract to pro%ide enough !lood flo- for-ard
!iastolic
!iastolic
(filling pro!lem$J
(filling pro!lem$J
ina!ility of the left %entricle
ina!ility of the left %entricle
to rela# normally, resulting in fluid !ac" up into the
to rela# normally, resulting in fluid !ac" up into the
lungs
lungs
"eft-sided
"eft-sided
J
J
ina!ility of the left %entricle to pump enough
ina!ility of the left %entricle to pump enough
!lood, causing fluid !ac" up into the lungs
!lood, causing fluid !ac" up into the lungs
#ight-sided
#ight-sided
J
J
inefficient pumping of the right side of the
inefficient pumping of the right side of the
heart, causing fluid !uildup in the a!domen, legs, and
heart, causing fluid !uildup in the a!domen, legs, and
feet
feet
)eft'Sided "eart Failure
)eft'Sided "eart Failure
Signs D S!mtoms
Signs D S!mtoms
Dyspnea Dyspnea
Confusion Confusion
Ascites Ascites
Anore#ia Anore#ia
7ausea 7ausea
0ea"ness 0ea"ness
Classification of stages of
Classification of stages of
heart failure
heart failure
%tage * %tage *
At hi&h ris, of
heart fail%re
-)pertension
C-'
'ia.etes
/eta.oli( s).
Cardioto0in
1ta&e 2 1ta&e 2
1tr%(t%ral heart
disease 3itho%t
s)mptoms
LV remodelin&
LV h)pertroph)
Val4e disease
%tage C %tage C
1tr%(t%ral heart
disease
3ith s)mptoms
of heart fail%re
%tage . %tage .
5efra(tor)
heart fail%re
Classification of "F: Comarison
Classification of "F: Comarison
;etEeen ACC3A"A "F Stage and
;etEeen ACC3A"A "F Stage and
2F"A Functional Class
2F"A Functional Class
3
Hunt 'A et al+ J Am Coll Cardiol. 1223)54,1323K1335+
1
7e- Lor" Heart AssociationM>ittle ro-n and Company, 3N6B+ Adapted from, Farrell .H et al+ JAMA. 1221)14I,4N2K4NI+
ACC3A"A "F Stage
7
2F"A Functional Class
G
A At high ris? for heart failure %ut Eithout
structural heart disease or s!mtoms
of heart failure *eg# atients Eith
h!ertension or coronar! arter! disease+
; Structural heart disease %ut Eithout
s!mtoms of heart failure
C Structural heart disease Eith rior or
current s!mtoms of heart failure
D (efractor! heart failure reHuiring
secialiBed interventions
I As!mtomatic
II S!mtomatic Eith moderate e&ertion
I4 S!mtomatic at rest
III S!mtomatic Eith minimal e&ertion
2one
Current D Future Persectives
in the Treatment of "eart
Failure
Princiles of Treatment
Princiles of Treatment
'ystolic HF
'ystolic HF
Preload
Preload
Afterload
Afterload
Ionotropy
Ionotropy
7eurohumoral
7eurohumoral
acti%ity
acti%ity
ACE-I, eta-!loc"ers,
ACE-I, eta-!loc"ers,
and aldosterone
and aldosterone
antagonist are the
antagonist are the
mainstay of treatment
mainstay of treatment
O%-ectives of treatment in C"F
O%-ectives of treatment in C"F
7#
7#
Impro%e
Impro%e
rognosis
rognosis
, reduce mortality
, reduce mortality
1, Impro%e mor!idity, relie%e
1, Impro%e mor!idity, relie%e
s!mtoms
s!mtoms
- increase e#ercise capacity
- increase e#ercise capacity
- reduce fatigue and !reathlessness
- reduce fatigue and !reathlessness
- eliminate oedema and fluid retention
- eliminate oedema and fluid retention
5,
5,
Prevention
Prevention
- myocardial damage
- myocardial damage
- remodelling
- remodelling
- reoccurence of symptoms
- reoccurence of symptoms
- hospitalisation
- hospitalisation
Treatment of C$0
Correction of reversi(le causes Correction of reversi(le causes
$
,edications ,edications
.iuretics, *CE inhi(itors, (eta (lokers etc6 .iuretics, *CE inhi(itors, (eta (lokers etc6
$
-schemia -schemia
$
*rrhythmia# * fi(, flutter, P;T *rrhythmia# * fi(, flutter, P;T
$
"alvular heart disease "alvular heart disease
$
Thyroto/icosis and other high output status Thyroto/icosis and other high output status
$
%hunts %hunts
Treatment of heart failure
Treatment of heart failure
Pharmacologic
treatment
6ozit74 inotrop
'i&italis
Ne%roh%mor8lis
.lo,8d: 22, AC*i
'i%reti(%m
Vasodilator
Antiarrh)thmi8s
Non4pharmacologic treatment
5es)n(hronization 9C5:;
<C'
<A26
Assist de4i(e
%urgical<interventional
5e4as(%larisation
Val4e repla(ement
Ane%r)sm rese(tion
1%r&i(al remodelin&
1tem=(ell therap)
$eart transplantation
Drug Thera!
Drug Thera!
-nhi(ition of
NE9&4$9,&*+
activation
AC* inhi.itors
2eta.lo(,ers
Aldosterone
Anta&onists
'i&o0in
eduction of
%"4-ncrese
Contractility
-)dralazine
Nitrate
Ca=(hanell
2lo(,ers
<notropi( a&ents
Elimination
of oedema
'i%reti(s
"FSA G070
"FSA G070
Comrehensive "eart
Comrehensive "eart
Failure Practice
Failure Practice
,uideline
,uideline
/ey Recommendations
/ey Recommendations
Diuretics @ ACEI reduces the num!er of
sac"s on the -agon
Diuretics
Diuretics
symptoms
symptoms
, oedema
, oedema
, prognosis
, prognosis
RAA' acti%ation
RAA' acti%ation
(itrate, com!ine
(itrate, com!ine
Diuretic resistance
Diuretic resistance
65 All a4aila.le for oral or <V administration
)oo Diuretics
)oo Diuretics
Agent Agent Initial Dail! Initial Dail!
Dose Dose
Ma& Total Ma& Total
Dail! Dose Dail! Dose
Elimination: Elimination:
(enal I Met. (enal I Met.
Duration of Duration of
Action Action
Furosemide Furosemide G0'/0mg Hd or G0'/0mg Hd or
%id %id
900 mg 900 mg 961('861M 961('861M /'9 hrs /'9 hrs
;umetanide ;umetanide 0.6'7.0 mg Hd 0.6'7.0 mg Hd
or %id or %id
70 mg 70 mg 9G1(38J1M 9G1(38J1M 9'J hrs 9'J hrs
Torsemide Torsemide 70'G0 mg Hd 70'G0 mg Hd G00 mg G00 mg G01('J01M G01('J01M 7G'79 hrs 7G'79 hrs
Ethacr!nic Ethacr!nic
acid acid
G6'60 mg Hd G6'60 mg Hd
or %id or %id
G00 mg G00 mg 9K1('881M 9K1('881M 9 hrs 9 hrs
Aldosterone antagonists
Aldosterone antagonists
symptoms
symptoms
, prognosis
, prognosis
, mortality
, mortality
7LHA III, EF
7LHA III, EF
A
A
5EC
5EC
Renal dysfunction
Renal dysfunction
Hyper"alaemia
Hyper"alaemia
ACE
ACE
I and A(;
I and A(;
symptoms
symptoms
, prognosis
, prognosis
, mortality
, mortality
remodelling
remodelling
, myocardial fi!rosis
, myocardial fi!rosis
Hypotension
Hypotension
Cough
Cough
Angio-oedema
Angio-oedema
L';loc?ers
>imit the don"eyPs speed, thus sa%ing energy
*ntiarrhythmics
/ost (ommon (a%se of 1C' in these patients is /ost (ommon (a%se of 1C' in these patients is
4entri(%lar ta(h)arrh)thmia 4entri(%lar ta(h)arrh)thmia
6atients 3ith h>o s%stained V: or 1C' ? <C' implant 6atients 3ith h>o s%stained V: or 1C' ? <C' implant
6atients 3ith C-+ 3ith an e@e(tion fra(tion of less than 6atients 3ith C-+ 3ith an e@e(tion fra(tion of less than
3!A ma) re(ei4e <C' implant 3!A ma) re(ei4e <C' implant
Amiodarone for patients 3ith freB%ent V6Cs and at fi. Amiodarone for patients 3ith freB%ent V6Cs and at fi.
'ranedone for patients 3ith re(%rrent paro0)smal at fi.. 'ranedone for patients 3ith re(%rrent paro0)smal at fi..
"asodilators)$ydrala5ine and Nitrates
$
(eduction of afterload
(eduction of afterload
!y arteriolar %asodilatation
!y arteriolar %asodilatation
(
(
h!dralaBin
h!dralaBin
$
$
'i&o0in,
'i&ito0in
C%a.ain.
Inotroic Agents
>i"e the carrot placed in front of the don"ey
-notropic *gents
(hese are the drugs that impro%e myocardial
(hese are the drugs that impro%e myocardial
contractility (
contractility (: adrenergic agonists, dopaminergic agents, : adrenergic agonists, dopaminergic agents,
phosphodiesterase inhi!itors$, phosphodiesterase inhi!itors$,
.opamine .opamine
.o(utamine .o(utamine
,ilrinone, ,ilrinone,
*amrinone *amrinone
'e%eral studies sho-ed R mortality -ith oral inotropic agents 'e%eral studies sho-ed R mortality -ith oral inotropic agents
'o the only use for them no- is in acute sittings such as cardiogenic 'o the only use for them no- is in acute sittings such as cardiogenic
shoc shoc
"
"
"eart Failure: Thera!
"eart Failure: Thera!
Stage A: Stage A:
Control ris? factors# treat underl!ing chronic disease contri%utors Control ris? factors# treat underl!ing chronic disease contri%utors
Stage ;: Stage ;:
Stage C: Stage C:
Devices *%i'4 acing# Imlanta%le defi%rillators Devices *%i'4 acing# Imlanta%le defi%rillators
Stage D: Stage D:
"osice "osice
Parenteral %asodilators
Parenteral %asodilators
S
S
(nitroglycerin, nitroprusside, nesiritide$
(nitroglycerin, nitroprusside, nesiritide$
Inotropes
Inotropes
S
S
(milrinone or do!utamine$
(milrinone or do!utamine$
E%ee recommendations for stipulations and restrictions6
Device Thera!
Device Thera!
Indications
Indications
.oderate to se%ere CHF -ho ha%e failed .oderate to se%ere CHF -ho ha%e failed optimal optimal medical medical
therapy therapy
EFA52C EFA52C
Patients often not on optimal .edical R# Patients often not on optimal .edical R#
Patients referred too late- 7ot a ail ?ut Patients referred too late- 7ot a ail ?ut
Defi%rillators *ICD$s+
Defi%rillators *ICD$s+
"oE does a defi%rillator for
"oE does a defi%rillator for
sudden cardiac death Eor?M
sudden cardiac death Eor?M
Device
Shown:
Combination
Pacemaker &
Defibrillator
Intraaortic ;alloon Pum *IA;P+
Intraaortic ;alloon Pum *IA;P+
Decrease left ventricular stroke work and Decrease left ventricular stroke work and
myocardial oxygen requirements myocardial oxygen requirements
Most widely used form of mechanical circulatory Most widely used form of mechanical circulatory
support support
Indications for its use include Indications for its use include
Failure to wean from cardiopulmonary bypass Failure to wean from cardiopulmonary bypass
T6Eyo T6Eyo
CRI CRI
2eEer ,eneration Artificial "earts
2eEer ,eneration Artificial "earts
%iventricular
%iventricular
Cardio0est (AH
Percutaneous -ntervention
6:CA
2alloon An&ioplast)
1tents
'r%&=el%tin& stents
:rans=m)o(ardial
5e4as(%larization
Earl! infarct affecting left
ventricle
thrombus
PCI and "eart Failure
%urgery
for
$eart 0ailure
.
%urgery
Coronar) 5e4as(%larization
Val4%lar 1%r&er)
LV Ane%r)sm 6li(ation>5ese(tion
Ventri(%lar 5emodellin&
'ur%i%al rate
'ur%i%al rate
E years I2C
E years I2C
Christian ;arnard
Christian ;arnard
famil! "istor!
famil! "istor!
cigarette smo?ing
cigarette smo?ing
dia%etes mellitus
dia%etes mellitus
h!ertension
h!ertension
h!erliidemia
h!erliidemia
sedentar! life'st!le
sedentar! life'st!le
o%esit!
o%esit!
EHER(I?7A> A7GI7A
EHER(I?7A> A7GI7A
S
S RIEF EPI'?DE' R?DGH( ?7 L EHER(I?7 A7D RE>IE&ED RIEF EPI'?DE' R?DGH( ?7 L EHER(I?7 A7D RE>IE&ED
L RE'( ?7 7(G L RE'( ?7 7(G
D7'(A>E A7GI7A
D7'(A>E A7GI7A
S 7E0 ?7'E( S 7E0 ?7'E(
S CHA7GE I7 FREWDE7CLM'E&ERI(L S CHA7GE I7 FREWDE7CLM'E&ERI(L
S ?CCDR' A( RE'( S ?CCDR' A( RE'(
A.I
A.I
S 'E&ERE PER'I'(E7( 'L.P(?.' S 'E&ERE PER'I'(E7( 'L.P(?.'
S E>E&A(ED (R?P?7I7 S E>E&A(ED (R?P?7I7
ISC"EMIC C"EST PAI2: DIA,2OSIS
ISC"EMIC C"EST PAI2: DIA,2OSIS
31 >EAD E/G
31 >EAD E/G
- >oo" for '( segment ele%ation (at least
- >oo" for '( segment ele%ation (at least
3mm in t-o contiguous leads$
3mm in t-o contiguous leads$
- >oo" for '( segment depression
- >oo" for '( segment depression
- >oo" for ( -a%e in%ersions
- >oo" for ( -a%e in%ersions
- >oo" for W -a%es
- >oo" for W -a%es
- >oo" for ne- >
- >oo" for ne- >
- Al-ays compare to old E/Gs
- Al-ays compare to old E/Gs
EA, C"A2,ES I2 ISC"EMIC
EA, C"A2,ES I2 ISC"EMIC
"EA(T DISEASE
"EA(T DISEASE
'( 'EG.E7( ( 0A&E
'( 'EG.E7( ( 0A&E
DEPRE''I?7 II7&ER'I?7'
DEPRE''I?7 II7&ER'I?7'
ISC"EMIC C"EST PAI2:
ISC"EMIC C"EST PAI2:
DIA,2OSTIC TESTS
DIA,2OSTIC TESTS
CA(DIAC E2NFMES
CA(DIAC E2NFMES
' M!oglo%in
' M!oglo%in
S 0ill rise -ithin 5 hours, pea" -ithin B-N
S 0ill rise -ithin 5 hours, pea" -ithin B-N
hours, and return to !aseline -ithin 1B hrs+
hours, and return to !aseline -ithin 1B hrs+
-
-
CAM;
CAM;
S 0ill rise -ithin B hours, pea" -ithin 31- 1B
S 0ill rise -ithin B hours, pea" -ithin 31- 1B
hours and return to !aseline in 1-5 days
hours and return to !aseline in 1-5 days
-
-
T(OPO2I2 I
T(OPO2I2 I
S 0ill rise -ithin 6 hours, pea" in 31 hours
S 0ill rise -ithin 6 hours, pea" in 31 hours
and return to !aseline in 5-B days
and return to !aseline in 5-B days
$
Blood tests# %sed to e4al%ate ,idne) and th)roid
f%n(tion as 3ell as to (he(, (holesterol le4els and
the presen(e of anemia.
$
Chest 34ray# sho3s the size of )o%r heart and
3hether there is fl%id .%ild %p aro%nd the heart and
l%n&s.
$
Echocardiogram# sho3s a &raphi( o%tline of the
heartIs mo4ement
$
E1ection fraction (E0)# determines ho3 3ell )o%r
heart p%mps 3ith ea(h .eat.
Coronar! Arter! Angiograh!
Coronar! Arter! Angiograh!
Coronar! Arter! Angiograh!
Coronar! Arter! Angiograh!
Echocardiograh!
Echocardiograh!
Ischemic Heart Disease
Ischemic Heart Disease
Ischemic "eart Disease
Ischemic "eart Disease
I4US'Atherosclerotic PlaHue
I4US'Atherosclerotic PlaHue
'ta!le Angina
,*-N E3-T NE3T
Definition
T!es of Angina
Management of Angina
Antianginal drugs
Angina
Angina
Angina is a t!e of
Angina is a t!e of
chest discomfort
chest discomfort
caused %! oor %lood
caused %! oor %lood
floE through the %lood
floE through the %lood
vessels *coronar!
vessels *coronar!
vessels+ of the heart
vessels+ of the heart
muscle *m!ocardium+.
muscle *m!ocardium+.
Chest ain caused %! transient
myocardial ischemia due to an
im%alance %etEeen m!ocardial
o&!gen sul! and demand.
35N
B*C2 ,*-N E3-T -N.E3 NE3T
Transient M!ocardial Transient M!ocardial
ischemia ischemia
Severe Chest ain
Severe Chest ain
M!ocardial ;lood FloE
M!ocardial OG Demands
Angina Pectoris
3B2
B*C2 ,*-N E3-T -N.E3 NE3T
$ypes of Angina
$ypes of Angina
7. Sta%le Angina.
3B3
B*C2 ,*-N E3-T -N.E3 NE3T
G. Unsta%le Angina.
8. 4ariant Angina.
Sta%le Angina ' S!mtoms
Sta%le Angina ' S!mtoms
Asirin'
Asirin'
Decrease throm%otic risc
Decrease throm%otic risc
Decrease M4OG
Decrease M4OG
nitrates
nitrates
%eta'%loc?ers
%eta'%loc?ers
ACE'inhi%itors
ACE'inhi%itors
2on'Transmural M!ocardial Infarction *2TMI or SEMI+ 2on'Transmural M!ocardial Infarction *2TMI or SEMI+
2o V Eaves 2o V Eaves
ST elevation ST elevation
Q V Eaves Q V Eaves
The initial
The initial
ECG in patients with
ECG in patients with
NSTEMI does not show ST-segment
NSTEMI does not show ST-segment
elevation.
elevation.
Full thic"ness
Full thic"ness
'uperimposed
'uperimposed
throm!us in
throm!us in
atherosclerosis
atherosclerosis
Focal damage
Focal damage
Su%'endocardial *2STEMI+ Su%'endocardial *2STEMI+
Circumferential Circumferential
Heart ! 4athology
Heart ! 4athology
Ischemic "eart Disease Ischemic "eart Disease
TTC TTC
Diagnosis of .I,
Role of troponin i
1: se&ment
ele4ation
1: se&ment
depression
: 3a4e in4ersion
L 3a4e formation
ACUTE I2FE(IO( MI
ACUTE I2FE(IO( MI
reerfusion thera!
reerfusion thera!
throm%ol!tic thera! *t'PA# SA# n'PA# r' PA+ throm%ol!tic thera! *t'PA# SA# n'PA# r' PA+
neE com%inations * t'PA# r'PA Q G% 3 8a inhi%+ neE com%inations * t'PA# r'PA Q G% 3 8a inhi%+
decrease M4OG
decrease M4OG
nitrates# %eta %loc?ers and ACE inhi%itors nitrates# %eta %loc?ers and ACE inhi%itors
for high PC@P ' diuretics for high PC@P ' diuretics
for loE Cardiac Outut ' ressors *doamine# levohed# for loE Cardiac Outut ' ressors *doamine# levohed#
do%utamineS IA;PS earl! catheteriBation do%utamineS IA;PS earl! catheteriBation
Fi%rinol!tic Thera!
Fi%rinol!tic Thera!
in STEMI
in STEMI
Coagulation and Fi%rinol!sis
Coagulation and Fi%rinol!sis
0i(rinolysis 0i(rinolysis
0i(rin
Coagulation 0actors
0i(rinogen
Plasmin
Plasminogen
Tissue Plasminogen
*ctivator
0i(rinolysis
0i(rinolysis
Aside: other Anti'throm%otic drug t!es
Aside: other Anti'throm%otic drug t!es
cloidogrel cloidogrel
di!ridamole di!ridamole
ticloidine ticloidine
tissue lasminogen activator ' t'PA ' altelase *Activase+ tissue lasminogen activator ' t'PA ' altelase *Activase+
The lasmin*ogen+ molecule has l!sine %inding sites# Ehich The lasmin*ogen+ molecule has l!sine %inding sites# Ehich
%ind to and degrade fi%rin %ind to and degrade fi%rin
Fi%rin'secific agents are much more active uon %inding to Fi%rin'secific agents are much more active uon %inding to
fi%rin# there%! increasing the affinit! for lasminogen at the fi%rin# there%! increasing the affinit! for lasminogen at the
clot surface clot surface
Throm(olytic .rugs
Throm(olytic .rugs
It is a !acterial protein produced !y group C It is a !acterial protein produced !y group C 5beta6 5beta6-hemolytic -hemolytic
streptococci streptococci
Mechanism:
Mechanism: It !inds to plasminogen producing an It !inds to plasminogen producing an Ractivator Ractivator
comle& comle&X X that lyses free plasminogen to the proteolytic en;yme that lyses free plasminogen to the proteolytic en;yme
plasmin plasmin
Plasmin degrades Plasmin degrades fi!rin fi!rin clots as -ell as clots as -ell as fi!rinogen fi!rinogen and other and other
plasma proteins (non-fi!rin specific$ plasma proteins (non-fi!rin specific$
O
Pharmaco"inetics, Pharmaco"inetics,
(he t (he t
Y Y
of the acti%ator comple# is a!out 15 minutes of the acti%ator comple# is a!out 15 minutes
(he comple# is inacti%ated !y anti-streptococcal anti!odies @ !y (he comple# is inacti%ated !y anti-streptococcal anti!odies @ !y
hepatic clearance hepatic clearance
Throm(olytic .rugs
Throm(olytic .rugs
*lteplase (rt6P*)
*lteplase (rt6P*)
O
It is It is a tissue plasminogen acti+ator (t.PA, a tissue plasminogen acti+ator (t.PA, produced !y produced !y
recom!inant D7A technology of E1I amino acids recom!inant D7A technology of E1I amino acids
O
Cost per day is around 1122 Z Cost per day is around 1122 Z
O
Mechanism: Mechanism:
It is It is an en/yme an en/yme -hich has the property of fi!rin-enhanced -hich has the property of fi!rin-enhanced
con%ersion of plasminogen to plasmin con%ersion of plasminogen to plasmin
It produces limited con%ersion of free plasminogen in the It produces limited con%ersion of free plasminogen in the
a!sence of fi!rin a!sence of fi!rin
0hen introduced into the systemic circulation it !inds to fi!rin in 0hen introduced into the systemic circulation it !inds to fi!rin in
a throm!us and con%erts the entrapped plasminogen to plasmin a throm!us and con%erts the entrapped plasminogen to plasmin
follo-ed !y acti%ated local fi!rinolysis -ith limited systemic follo-ed !y acti%ated local fi!rinolysis -ith limited systemic
proteolysis proteolysis
Throm(olytic .rugs
Throm(olytic .rugs
Theraeutic Uses
Theraeutic Uses
O
Acute M!ocardial Infarction
Acute M!ocardial Infarction
in adults for the
in adults for the
impro%ement of %entricular function follo-ing A.I
impro%ement of %entricular function follo-ing A.I
the reduction of the incidence of congesti%e heart
the reduction of the incidence of congesti%e heart
failure, and the reduction of mortality associated -ith
failure, and the reduction of mortality associated -ith
A.I
A.I
O
Acute Ischemic Stro?e
Acute Ischemic Stro?e
for impro%ing neurological
for impro%ing neurological
reco%ery and reducing the incidence of disa!ility+
reco%ery and reducing the incidence of disa!ility+
(reatment should only !e initiated -ithin 5 hours after
(reatment should only !e initiated -ithin 5 hours after
the onset of stro"e symptoms, and after e#clusion of
the onset of stro"e symptoms, and after e#clusion of
intracranial hemorrhage
intracranial hemorrhage
O
Pulmonar! Em%olism
Pulmonar! Em%olism
:
:
(reatment of acute massi%e
(reatment of acute massi%e
pulmonary em!olism
pulmonary em!olism
Reteplase & Tenectaplase
Reteplase & Tenectaplase
O
(etelase
(etelase
is another human t-PA prepared !y
is another human t-PA prepared !y
recom!inant mutation technology
recom!inant mutation technology
-
It is fi!rin-specific
It is fi!rin-specific
-
It has longer duration than alteplase
It has longer duration than alteplase
O
Tenectalase
Tenectalase
is another genetically modified
is another genetically modified
human t-PA prepared !y recom!inant
human t-PA prepared !y recom!inant
technology
technology
-
It is more fi!rin-specific @ longer duration than
It is more fi!rin-specific @ longer duration than
alteplase
alteplase
:hrom.ol)ti( 'r%&s
:hrom.ol)ti( 'r%&s
9rokinase
9rokinase
O
It is an
It is an
en;yme
en;yme
produced !y the
produced !y the
"idney
"idney
, and
, and
found in the urine
found in the urine
O
It is mainly used in the lo- molecular -eight
It is mainly used in the lo- molecular -eight
form of uro"inase o!tained from human
form of uro"inase o!tained from human
neonatal "idney cells gro-n in tissue culture
neonatal "idney cells gro-n in tissue culture
O
.echanism,
.echanism,
It acts on the endogenous
It acts on the endogenous
fi!rinolytic system con%erting plasminogen
fi!rinolytic system con%erting plasminogen
to the en;yme plasmin that degrades fi!rin
to the en;yme plasmin that degrades fi!rin
clots as -ell as fi!rinogen and some other
clots as -ell as fi!rinogen and some other
plasma proteins (
plasma proteins (
7on-fi!rin selecti%e
7on-fi!rin selecti%e
$
$
Throm(olytic .rugs
Throm(olytic .rugs
9rokinase
9rokinase
Clinical Dses,
Clinical Dses,
"earin
"earin
meta'anal!ses
meta'anal!ses
*7#G+ *7#G+
of si& trials shoEed a 881
of si& trials shoEed a 881
ris? reduction in MI and death# %ut Eith a tEo
ris? reduction in MI and death# %ut Eith a tEo
fold increase in ma-or %leeding
fold increase in ma-or %leeding
)oE'molecular'Eeight hearin
)oE'molecular'Eeight hearin
ad%antages o%er heparin,
ad%antages o%er heparin,
%etter %io'availa%ilit!
%etter %io'availa%ilit!
Positive: Positive:
J01 angina free after 6 !ears J01 angina free after 6 !ears
Survival a%out P61 after 7 !ear Survival a%out P61 after 7 !ear
2egative: 2egative:
G'8 da!s in ICU# K'70 da! total hosital sta! G'8 da!s in ICU# K'70 da! total hosital sta!
8'9 month full recover! time 8'9 month full recover! time
Deression of the atient5s immune s!stem Deression of the atient5s immune s!stem
Postoerative %leeding from inactivation of the %lood clotting s!stem Postoerative %leeding from inactivation of the %lood clotting s!stem
"!otension "!otension
2J -arlan, et al; Manual of Cardiac Surgery, WebMD.com, American College of Cardiology Foundation
'maller incision
'maller incision
>&EDP ele%ation
Hypotension
Decreased coronary
perfusion
Ischemia
Further myocardial
dysfunction
7eurohormonal
acti%ation
&asoconstriction
Endorgan hypoperfusion
Currently,
Currently,
stenting is recommended over surger!
stenting is recommended over surger!
for one'vessel disease
for one'vessel disease
In the future, drug-eluting stents -ill pro!a!ly !e used In the future, drug-eluting stents -ill pro!a!ly !e used
Minimall! invasive surgeries could %e used in lace of Minimall! invasive surgeries could %e used in lace of
stents in dia%etic# and other high'ris? atients stents in dia%etic# and other high'ris? atients
Minimall! invasive surgeries Eill e&and and relace Minimall! invasive surgeries Eill e&and and relace
most conventional CA;, rocedures most conventional CA;, rocedures
VUESTIO2S MMM
THE END
Bine ca s-a terminat !!! Bine ca s-a terminat !!!
,yosplint
Chan&e in radi%s
51
5F
Infarct in ventricular Eall Eith loss of muscle and
scarring
VUESTIO2S MMM
D6 $ypertrophy L
.ilatation
E6.6"
=6 %ympathetic activity#
1
1 ".(.
8 4.C
*ngiotensine
*ldosterone
Positive
Inotroics
Diuretics
ACE
inhi%itors
vasodilators
Treatment of heart failure
Pharmacological $reatment
!iuretics
(loop diuretics< thia/ide diuretics
and potassium sparing diuretics,
(hese act !y promoting the renal e#cretion of
salt and -ater !y !loc"ing tu!ular rea!sorption
of sodium and chloride+ (he resulting loss of
fluid reduces %entricular filling pressures
(preload$, produces consistent haemodynamic
and symptomatic !enefits and rapidly impro%es
dyspnoea and peripheral oedema+
ca
KK
*TPase
ca
QQ
Na
K
<n therape%ti( dose leads to partial inhi.ition of Na
D
>O
D
A:6ase enz)me
Na
K
Na
K
Na
K
Na
K Na
K
Na
K
O intracellular Na
K
resulting in#
2a
K
3ca
K K
e&change
ca
QQ
Na
K
A
Q
ca
QQ
ca
QQ
ca
QQ
sar(oplasmi( reti(%l%m
ca
QQ
ca
QQ
ca
QQ ca
QQ
ca
QQ
ca
QQ
ca
QQ
ca
QQ
troponin
*ctin ,yosin
0orce &f Contractility
'ur%i%al rate
'ur%i%al rate
E years I2C
E years I2C
Christian ;arnard
Christian ;arnard
Fluid
olus
>egs up
Rhythm
(amponade
leeding
Drains, CHR, H!
Pneumothora#
Fight &entilator
?hms >a-
&[I # R
P[C? # '&R
'imple terms
Increases HR
C?['& # HR
Ca
GQ
Inotrope and
%asoconstrictor
'hort acting
(achycardia
&A'?DI>A(?R
e-are
&asodilated patients
Do%utamine
>i"e dopamine
&asoconstrictor
e-are %asodilated
patients
Eno&imone
6hosphodiesterase <nhi.itor
Nood in patients 3ith hi&h 6A press%re
JFnd line 3hen adrenaline ha4in& no
effe(t Jre(eptor disso(iationK
Aminoh!lline
Phosphodiesterase
inhi!itor
1
nd
line %asoconstrictor
Indications
Indications
.oderate to se%ere CHF -ho ha%e failed .oderate to se%ere CHF -ho ha%e failed optimal optimal medical medical
therapy therapy
EFA52C EFA52C
Patients often not on optimal .edical R# Patients often not on optimal .edical R#
Patients referred too late- 7ot a ail ?ut Patients referred too late- 7ot a ail ?ut
&entricular remodelling
&entricular remodelling
E/citation4contraction
coupling
.ysrhythmias N
Electrical dyssynchrony
,echanical dyssynchrony
Defi%rillators *ICD$s+
Defi%rillators *ICD$s+
2eEer ,eneration Artificial "earts
2eEer ,eneration Artificial "earts
Future Tech
Future Tech
"eart Failure: Thera!
"eart Failure: Thera!
Stage A: Stage A:
Control ris? factors# treat underl!ing chronic disease contri%utors Control ris? factors# treat underl!ing chronic disease contri%utors
Stage ;: Stage ;:
Stage C: Stage C:
Devices *%i'4 acing# Imlanta%le defi%rillators Devices *%i'4 acing# Imlanta%le defi%rillators
Stage D: Stage D:
"osice "osice
First option if the cause of heart failure can !e treated First option if the cause of heart failure can !e treated
surgically surgically
'e%eral therapeutic options, pacing, an ICD, a %entricular 'e%eral therapeutic options, pacing, an ICD, a %entricular
assist de%ice, an artificial heart, or a heart transplant assist de%ice, an artificial heart, or a heart transplant
Pacing or resynchroni;ation therapy is recommended for Pacing or resynchroni;ation therapy is recommended for
patients -ith 7LHA Class III or I& -ith WR' prolongation patients -ith 7LHA Class III or I& -ith WR' prolongation
-ho are e#periencing symptoms despite medications -ho are e#periencing symptoms despite medications
De%ices and 'urgical .anagement
De%ices and 'urgical .anagement
An ICD may !e used in patients -ith arrhythmias to pre%ent An ICD may !e used in patients -ith arrhythmias to pre%ent
sudden cardiac death sudden cardiac death
A left %entricular assist de%ice may !e used as a !ridge to A left %entricular assist de%ice may !e used as a !ridge to
transplant or destination therapy transplant or destination therapy
End-stage heart failure patients may consider heart transplant End-stage heart failure patients may consider heart transplant
Diagnosis of heart failure
Diagnosis of heart failure
ECG 31 leads
ECG 31 leads
Chest H-ray
Chest H-ray
Echocardiography (systolicMdiastolic
Echocardiography (systolicMdiastolic
dysfunction, structural heart disease$
dysfunction, structural heart disease$
spiroergometry
spiroergometry
Diagnosis of heart failure
Diagnosis of heart failure
Ph!sical e&amination
Medical histor!
)a% tests: ;2P# <
='ra!# EC,#
Echo# Siro'
Ergometr!<
ACE inhi!itors
ACE inhi!itors
symptoms
symptoms
, prognosis
, prognosis
, mortality
, mortality
remodelling
remodelling
, myocardial fi!rosis
, myocardial fi!rosis
Hypotension
Hypotension
Cough
Cough
Angio-oedema
Angio-oedema
eta!loc"ers
eta!loc"ers
symptoms
symptoms
, prognosis
, prognosis
, mortality
, mortality
remodelling
remodelling
, dyssynchrony
, dyssynchrony
'CD
'CD
, antiarrhythmic effect
, antiarrhythmic effect
Hypotension
Hypotension
Fatigue
Fatigue
radycardia, !loc"
radycardia, !loc"
symptoms
symptoms
, prognosis
, prognosis
, mortality
, mortality
7LHA III, EF
7LHA III, EF
A
A
5EC
5EC
Renal dysfunction
Renal dysfunction
Hyper"alaemia
Hyper"alaemia
Diuretics
Diuretics
symptoms
symptoms
, oedema
, oedema
, prognosis
, prognosis
RAA' acti%ation
RAA' acti%ation
(itrate, com!ine
(itrate, com!ine
Diuretic resistance
Diuretic resistance
Patients 'ith acute heart failure
freOuently develop chronic heart failure6
Patients 'ith chronic heart failure
freOuently decompensate acutely6
"EA(T FAI)U(E
"EA(T FAI)U(E
52B
Multi'Discilinar!
Multi'Discilinar!
"eart Failure
"eart Failure
Management
Management
52E
Clinical Classifications
Clinical Classifications
S!stolic:
S!stolic:
Impaired a!ility of the heart to contract Impaired a!ility of the heart to contract
0ea"ened muscle, enlarged heart si;e 0ea"ened muscle, enlarged heart si;e
>eft %entricular eFection fraction (>&EF$ A B2KBEC >eft %entricular eFection fraction (>&EF$ A B2KBEC
Diastolic,
Diastolic,
ina!ility of the heart to rela# is impaired ina!ility of the heart to rela# is impaired
'tiff, thic"ened myocardial -all !ut normal si;e 'tiff, thic"ened myocardial -all !ut normal si;e
>&EF >&EF
BEC BEC
526
Clinical Classifications
Clinical Classifications
Acute
Acute
Chronic
Chronic
Acute Decomensated
Acute Decomensated
Decreased pumping function of the heart, -hich results in Decreased pumping function of the heart, -hich results in
fluid !ac" up in the lungs and heart failure fluid !ac" up in the lungs and heart failure
In%ol%es a thic"ened and stiff heart muscle In%ol%es a thic"ened and stiff heart muscle
As a result, the heart does not fill -ith !lood properly As a result, the heart does not fill -ith !lood properly
(his results in fluid !ac"up in the lungs and heart failure (his results in fluid !ac"up in the lungs and heart failure
CAD[coronary artery disease) >&H[left %entricular hypertrophy+
(is? Factors for "eart Failure
(is? Factors for "eart Failure
Hypertension (>&H$
Hypertension (>&H$
Alcoholism
Alcoholism
Infection (%iral$
Infection (%iral$
Dia!etes
Dia!etes
?ther,
?ther,
?!esity ?!esity
Age Age
'mo"ing 'mo"ing
.edical history is ta"en to re%eal symptoms .edical history is ta"en to re%eal symptoms
(ests (ests
Electrical tracing of heart (Electrocardiogram or ^ECG_$ Electrical tracing of heart (Electrocardiogram or ^ECG_$
H-ray of the inside of !lood %essels (Angiogram$ H-ray of the inside of !lood %essels (Angiogram$
Pathoh!siolog!
Pathoh!siolog!
Adapted from Cohn JN. N Engl J Med. 1996;335:9!"9#.
Pathologic
remodeling
+o' e1ection
fraction
.eath
%ymptoms#
.yspnea
0atigue
Edema
Chronic
heart
failure
$
Neurohormonal
stimulation
$ ,yocardial
to/icity
%udden
.eath
Pump
failure
Coronary artery
disease
$ypertension
Cardiomyopathy
"alvular disease
,yocardial
in1ury
Pathologic Progression of C4 Disease
Pathologic Progression of C4 Disease
.ia(etes
Comensator! Mechanisms:
Comensator! Mechanisms:
(enin'Angiotensin'Aldosterone S!stem
(enin'Angiotensin'Aldosterone S!stem
enin K *ngiotensinogen
*ngiotensin -
*ngiotensin --
Peripheral
"asoconstriction
*fterload
Cardiac &utput
$eart 0ailure $eart 0ailure
Cardiac 8orkload
Preload
Plasma "olume
%alt L 8ater etention
Edema
*ldosterone %ecretion
*CE
2aliuresis
Beta Beta
%timulation %timulation
$
C& C&
$
Na Na
K K
0i(rosis
Drug Thera!
Drug Thera!
"eart Failure Treatments:
"eart Failure Treatments:
Medication T!es
Medication T!es
ACE inhibitor
(angiotensin-conerting
enzyme!
A"# (angiotensin receptor
bloc$ers!
#eta-bloc$er
%igo&in
%iuretic
Aldosterone
bloc$ade
'ype (hat it does
E&pands blood essels which lowers
blood pressure) neurohormonal
bloc$ade
*imilar to ACE inhibitor+lowers
blood pressure
"educes the action of stress
hormones and slows the heart rate
*lows the heart rate and improes the
heart,s pumping function (EF!
Filters sodium and e&cess fluid from the
blood to reduce the heart,s wor$load
#loc$s neurohormal actiation and controls
olume
(ational for Medications
(ational for Medications
*@h! does m! doctor have me on so
*@h! does m! doctor have me on so
man! illsMM+
man! illsMM+
Impro%e 'ymptoms
Impro%e 'ymptoms
digo#in digo#in
Impro%e 'ur%i%al
Impro%e 'ur%i%al
eta!loc"ers eta!loc"ers
ACE-inhi!itors ACE-inhi!itors
RAA' Inhi!itors,
RAA' Inhi!itors,
ACE IMARs
ACE IMARs
Aldosterone Antagonists
Aldosterone Antagonists
eta loc"ers
eta loc"ers
'7' Inhi!itors,
'7' Inhi!itors,
eta loc"ers
eta loc"ers
Isor!ide dinitrateMhydral;ine
Isor!ide dinitrateMhydral;ine
3F#
ACE Inhi%itors
ACE Inhi%itors
Controls HR and P
Controls HR and P
33!
;eta ;loc?ers: 8 Indicated
;eta ;loc?ers: 8 Indicated
Metorolol =)
Metorolol =)
( !eta 3 selecti%e$, .ERI( HF
( !eta 3 selecti%e$, .ERI( HF
Carvedilol
Carvedilol
(!eta 3, !eta 1, alpha !loc"ade$
(!eta 3, !eta 1, alpha !loc"ade$
C?PER7ICD', C?.E(
C?PER7ICD', C?.E(
;isorolol
;isorolol
(CII' II$
(CII' II$
O2)F
O2)F
Comet trial
Comet trial
331
"oE to give ;eta ;loc?ers
"oE to give ;eta ;loc?ers
Patient should !e
Patient should !e
eu+olemic
eu+olemic
prior to starting) neg+
prior to starting) neg+
inotropic
inotropic
action, increased preload can e#acer!ate
action, increased preload can e#acer!ate
fluid o%erload+
fluid o%erload+
Promotes salt and -ater retention, /\ and .g loss) Promotes salt and -ater retention, /\ and .g loss)
sympathetic stimulation and parasympathetic inhi!ition, sympathetic stimulation and parasympathetic inhi!ition,
!aroreceptor dysfunction, %ascular damage and impaired !aroreceptor dysfunction, %ascular damage and impaired
arterial compliance+ arterial compliance+
(A)ES: (A)ES: ('pironolactone$, ('pironolactone$, 801 801 ris" reduction in mortality ris" reduction in mortality
and and 861 861 reduction in HF admissions as compared -ith reduction in HF admissions as compared -ith
place!o) Real -orld`` Fe- on eta loc"ers place!o) Real -orld`` Fe- on eta loc"ers
EP"ESUS EP"ESUS,Eplerenone (Inspra$, post .I) ,Eplerenone (Inspra$, post .I) 761 761 ris" reduction ris" reduction
?7 current therapy HF meds) more specific) less '+E+ ?7 current therapy HF meds) more specific) less '+E+
(gynecomastia$ (gynecomastia$
A'"eFT 7 A'"eFT 7, Protecti%e role of nitric o#ide , Protecti%e role of nitric o#ide
Additional /81 reduction in mortalit! Ehen added to Additional /81 reduction in mortalit! Ehen added to
current standard thera! : *African Americans+ current standard thera! : *African Americans+
Decreased 3 Decreased 3
st st
hospitali;ation for HF !y 55C hospitali;ation for HF !y 55C
Ho- it -or"s, &asodilator, alance of arterio and Ho- it -or"s, &asodilator, alance of arterio and
%enodilation %enodilation
Hydrala;ine pre%ents degredation of n+o+ and prolongs Hydrala;ine pre%ents degredation of n+o+ and prolongs
%asodilatory effects of isosor!ide %asodilatory effects of isosor!ide
A reasona!le alternati%e for any patient -ho cannot ta"e A reasona!le alternati%e for any patient -ho cannot ta"e
ACEMARs ACEMARs
ZZZZZZZZZ ZZZZZZZZZ
336
S!mtom (elief
S!mtom (elief
Digo#in,
Digo#in,
2o mortalit! data
2o mortalit! data
) data on decreased
) data on decreased
hospitali;ations
hospitali;ations
Dse 5
Dse 5
rd rd
line for symptom relief
line for symptom relief
Inotroes
Inotroes
, 'till gi%en in ?P setting) for lo- c+o+
, 'till gi%en in ?P setting) for lo- c+o+
states) for s# relief) end stage HF only
states) for s# relief) end stage HF only
33#
"oE Do @e Predict SCD Post'MIM
"oE Do @e Predict SCD Post'MIM
P4Cs# 2onsustained 4T Ma! 2ot "el
P4Cs# 2onsustained 4T Ma! 2ot "el
2F"A II "F
2F"A II "F trength of )+idence > ? trength of )+idence > ?
"FSA G070 Practice ,uideline *K.G8+
"FSA G070 Practice ,uideline *K.G8+
Pharmacologic Thera!: Diuretics
Pharmacologic Thera!: Diuretics
Diuretic thera!
Diuretic thera!
is recommended
is recommended
to restore and
to restore and
maintain normal volume status in atients Eith
maintain normal volume status in atients Eith
clinical evidence of fluid overload# generall!
clinical evidence of fluid overload# generall!
manifested %!:
manifested %!:
Congestive s!mtoms
Congestive s!mtoms
)oo diuretics
)oo diuretics
rather than thiaBide't!e
rather than thiaBide't!e
diuretics are t!icall! necessar! to restore
diuretics are t!icall! necessar! to restore
normal volume status in atients Eith "F.
normal volume status in atients Eith "F.
trength trength
of )+idence > ? of )+idence > ?
3F All a4aila.le for oral or <V administration
)oo Diuretics
)oo Diuretics
Agent Agent Initial Dail! Initial Dail!
Dose Dose
Ma& Total Ma& Total
Dail! Dose Dail! Dose
Elimination: Elimination:
(enal I Met. (enal I Met.
Duration of Duration of
Action Action
Furosemide Furosemide G0'/0mg Hd or G0'/0mg Hd or
%id %id
900 mg 900 mg 961('861M 961('861M /'9 hrs /'9 hrs
;umetanide ;umetanide 0.6'7.0 mg Hd 0.6'7.0 mg Hd
or %id or %id
70 mg 70 mg 9G1(38J1M 9G1(38J1M 9'J hrs 9'J hrs
Torsemide Torsemide 70'G0 mg Hd 70'G0 mg Hd G00 mg G00 mg G01('J01M G01('J01M 7G'79 hrs 7G'79 hrs
Ethacr!nic Ethacr!nic
acid acid
G6'60 mg Hd G6'60 mg Hd
or %id or %id
G00 mg G00 mg 9K1('881M 9K1('881M 9 hrs 9 hrs
33 All a4aila.le for oral or <V administration
Potassium'Saring Diuretics
Potassium'Saring Diuretics
Agent Agent Initial Dail! Initial Dail!
Dose Dose
Ma& Total Ma& Total
Dail! Dose Dail! Dose
Elimination Elimination Duration Duration
of Action of Action
Sironolactone Sironolactone 7G.6'G6 mg 7G.6'G6 mg
Hd Hd
60 mg 60 mg Meta%olic Meta%olic /J'KG hrs /J'KG hrs
Elerenone Elerenone G6'60 mg Hd G6'60 mg Hd 700 mg 700 mg (enal# (enal#
Meta%olic Meta%olic
Un?noEn Un?noEn
Amiloride Amiloride 6 mg Hd 6 mg Hd G0 mg G0 mg (enal (enal G/ hrs G/ hrs
Triamterene Triamterene 60'K6 mg 60'K6 mg
%id %id
G00 mg G00 mg Meta%olic Meta%olic K'P hrs K'P hrs
"FSA G070 Practice ,uideline *P.7# P./+
"FSA G070 Practice ,uideline *P.7# P./+
Device Thera!:
Device Thera!:
Proh!lactic ICD Placement
Proh!lactic ICD Placement
Proh!lactic ICD lacement Proh!lactic ICD lacement should %e considered should %e considered in atients in atients
Eith an )4EF Y861 and mild to moderate "F s!mtoms: Eith an )4EF Y861 and mild to moderate "F s!mtoms:
Ischemic etiolog! Ischemic etiolog! trength of )+idence > A trength of )+idence > A
2on'ischemic etiolog! 2on'ischemic etiolog! trength of )+idence > ? trength of )+idence > ?
In atients Eho are undergoing imlantation of a In atients Eho are undergoing imlantation of a
%iventricular acing device# use of a device that rovides %iventricular acing device# use of a device that rovides
defi%rillation defi%rillation should %e considered. should %e considered. trength of )+idence > ? trength of )+idence > ?
Decisions should %e made in light of functional status and Decisions should %e made in light of functional status and
rognosis %ased on severit! of underl!ing "F and comor%id rognosis %ased on severit! of underl!ing "F and comor%id
conditions# ideall! after 8'9 mos. of otimal medical thera!. conditions# ideall! after 8'9 mos. of otimal medical thera!.
trength of )+idence > C trength of )+idence > C
Adapted from:
"FSA G070 Practice ,uideline *77.7'77.G+
"FSA G070 Practice ,uideline *77.7'77.G+
"F Eith Preserved )4EFC
"F Eith Preserved )4EFC
Diagnosis
Diagnosis
Treatments ma! differ %ased on cardiac disorder. Treatments ma! differ %ased on cardiac disorder.
Evaluation for ischemic disease and induci%le Evaluation for ischemic disease and induci%le
m!ocardial ischemia should %e included. m!ocardial ischemia should %e included.
Echocardiograh! Echocardiograh!
Electrocardiograh! Electrocardiograh!
Stress imaging *via e&ercise or harmacologic means# using Stress imaging *via e&ercise or harmacologic means# using
m!ocardial erfusion or echocardiograhic imaging+ m!ocardial erfusion or echocardiograhic imaging+
Impro%e symptoms, especially congestion and lo--output Impro%e symptoms, especially congestion and lo--output
symptoms symptoms
?ptimi;e chronic oral therapy) minimi;e side effects ?ptimi;e chronic oral therapy) minimi;e side effects
Identify -ho might !enefit from re%asculari;ation Identify -ho might !enefit from re%asculari;ation
Education patients concerning medication and HF self-assessment Education patients concerning medication and HF self-assessment
Consider enrollment in a disease management program Consider enrollment in a disease management program
Strengt# of E$idence % C
HF'A 1232 Practice Guideline (31+E-31+12$ HF'A 1232 Practice Guideline (31+E-31+12$
OvervieE of Treatment Otions for Patients
OvervieE of Treatment Otions for Patients
Eith Acute Decomensated "F
Eith Acute Decomensated "F
Parenteral %asodilators
Parenteral %asodilators
S
S
(nitroglycerin, nitroprusside, nesiritide$
(nitroglycerin, nitroprusside, nesiritide$
Inotropes
Inotropes
S
S
(milrinone or do!utamine$
(milrinone or do!utamine$
E%ee recommendations for stipulations and restrictions6
Device Thera!:
Device Thera!:
;iventricular Pacing
;iventricular Pacing
Imlanta%le Cardiac Defri%rillators
Imlanta%le Cardiac Defri%rillators
E;M Theraies E;M Theraies (elative (is? (elative (is?
(eduction (eduction
Mortalit! Mortalit!
G !ear G !ear
ACE'I ACE'I 15C 15C 1IC 1IC
Z Z';loc?ers ';loc?ers 5EC 5EC 31C 31C
Aldosterone Aldosterone
Antagonists Antagonists
52C 52C 3NC 3NC
ICD ICD 53C 53C 4+EC 4+EC
351 C4er4ie3 of 'e4i(e :herap)
;iventricular Pacing
;iventricular Pacing
4entricular D!s!nchron!
4entricular D!s!nchron!
Indications
Indications
.oderate to se%ere CHF -ho ha%e failed .oderate to se%ere CHF -ho ha%e failed optimal optimal medical medical
therapy therapy
EFA52C EFA52C
Patients often not on optimal .edical R# Patients often not on optimal .edical R#
Patients referred too late- 7ot a ail ?ut Patients referred too late- 7ot a ail ?ut
Defi%rillators *ICD$s+
Defi%rillators *ICD$s+
"eart Failure and Sudden Cardiac
"eart Failure and Sudden Cardiac
Death
Death
'udden Cardiac Death ('CD$
'udden Cardiac Death ('CD$
Lour heart Lour heart suddenly suddenly goes into a %ery fast and chaotic rhythm goes into a %ery fast and chaotic rhythm
and stops pumping !lood and stops pumping !lood
Caused !y an ^electrical_ pro!lem in your heart Caused !y an ^electrical_ pro!lem in your heart
'CD is one of the leading causes of death in the D+'+ K 'CD is one of the leading causes of death in the D+'+ K
appro#imately BE2,222 deaths a year appro#imately BE2,222 deaths a year
Patients -ith heart failure are 6-N times as li"ely to de%elop Patients -ith heart failure are 6-N times as li"ely to de%elop
sudden cardiac death as the general population sudden cardiac death as the general population
"oE does a defi%rillator for
"oE does a defi%rillator for
sudden cardiac death Eor?M
sudden cardiac death Eor?M
Device
Shown:
Combination
/acema$er 0
%efibrillator
@ho should Consider an ICDM
@ho should Consider an ICDM
(ransplant
(ransplant
Artificial hearts
Artificial hearts
E%idence-ased
E%idence-ased
'ymptomatic Relief
'ymptomatic Relief
Chronic Heart Failure,
.edications Rationale
3M!
Evidence';ased Medications
Evidence';ased Medications
Counteract "F Comensator!
Counteract "F Comensator!
Mechanisms
Mechanisms
Goals,
Goals,
RAA' Inhi!itors,
RAA' Inhi!itors,
ACE IMARs
ACE IMARs
Aldosterone Antagonists
Aldosterone Antagonists
eta loc"ers
eta loc"ers
'7' Inhi!itors,
'7' Inhi!itors,
eta loc"ers
eta loc"ers
Isor!ide dinitrateMhydral;ine
Isor!ide dinitrateMhydral;ine
3MF
ACE Inhi%itors
ACE Inhi%itors
Controls HR and P
Controls HR and P
3M
;eta ;loc?ers: 8 Indicated
;eta ;loc?ers: 8 Indicated
Metorolol =)
Metorolol =)
( !eta 3 selecti%e$, .ERI( HF
( !eta 3 selecti%e$, .ERI( HF
Carvedilol
Carvedilol
(!eta 3, !eta 1, alpha !loc"ade$
(!eta 3, !eta 1, alpha !loc"ade$
C?PER7ICD', C?.E(
C?PER7ICD', C?.E(
;isorolol
;isorolol
(CII' II$
(CII' II$
O2)F
O2)F
Comet trial
Comet trial
3M5
"oE to give ;eta ;loc?ers
"oE to give ;eta ;loc?ers
Patient should !e
Patient should !e
eu+olemic
eu+olemic
prior to starting) neg+
prior to starting) neg+
inotropic
inotropic
action, increased preload can e#acer!ate
action, increased preload can e#acer!ate
fluid o%erload+
fluid o%erload+
Promotes salt and -ater retention, /\ and .g loss) Promotes salt and -ater retention, /\ and .g loss)
sympathetic stimulation and parasympathetic inhi!ition, sympathetic stimulation and parasympathetic inhi!ition,
!aroreceptor dysfunction, %ascular damage and impaired !aroreceptor dysfunction, %ascular damage and impaired
arterial compliance+ arterial compliance+
(A)ES: (A)ES: ('pironolactone$, ('pironolactone$, 801 801 ris" reduction in mortality ris" reduction in mortality
and and 861 861 reduction in HF admissions as compared -ith reduction in HF admissions as compared -ith
place!o) Real -orld`` Fe- on eta loc"ers place!o) Real -orld`` Fe- on eta loc"ers
EP"ESUS EP"ESUS,Eplerenone (Inspra$, post .I) ,Eplerenone (Inspra$, post .I) 761 761 ris" reduction ris" reduction
?7 current therapy HF meds) more specific) less '+E+ ?7 current therapy HF meds) more specific) less '+E+
(gynecomastia$ (gynecomastia$
A'"eFT 7 A'"eFT 7, Protecti%e role of nitric o#ide , Protecti%e role of nitric o#ide
Additional /81 reduction in mortalit! Ehen added to Additional /81 reduction in mortalit! Ehen added to
current standard thera! : *African Americans+ current standard thera! : *African Americans+
Decreased 3 Decreased 3
st st
hospitali;ation for HF !y 55C hospitali;ation for HF !y 55C
Ho- it -or"s, &asodilator, alance of arterio and Ho- it -or"s, &asodilator, alance of arterio and
%enodilation %enodilation
Hydrala;ine pre%ents degredation of n+o+ and prolongs Hydrala;ine pre%ents degredation of n+o+ and prolongs
%asodilatory effects of isosor!ide %asodilatory effects of isosor!ide
A reasona!le alternati%e for any patient -ho cannot ta"e A reasona!le alternati%e for any patient -ho cannot ta"e
ACEMARs ACEMARs
ZZZZZZZZZ ZZZZZZZZZ
3#!
S!mtom (elief
S!mtom (elief
Digo#in,
Digo#in,
2o mortalit! data
2o mortalit! data
) data on decreased
) data on decreased
hospitali;ations
hospitali;ations
Dse 5
Dse 5
rd rd
line for symptom relief
line for symptom relief
Inotroes
Inotroes
, 'till gi%en in ?P setting) for lo- c+o+
, 'till gi%en in ?P setting) for lo- c+o+
states) for s# relief) end stage HF only
states) for s# relief) end stage HF only
3#F
"oE Do @e Predict SCD Post'MIM
"oE Do @e Predict SCD Post'MIM
P4Cs# 2onsustained 4T Ma! 2ot "el
P4Cs# 2onsustained 4T Ma! 2ot "el
>&EF a5EC
>&EF a5EC
2F"A II "F
2F"A II "F trength of )+idence > ? trength of )+idence > ?
"FSA G070 Practice ,uideline *K.G8+
"FSA G070 Practice ,uideline *K.G8+
Pharmacologic Thera!: Diuretics
Pharmacologic Thera!: Diuretics
Diuretic thera!
Diuretic thera!
is recommended
is recommended
to restore and
to restore and
maintain normal volume status in atients Eith
maintain normal volume status in atients Eith
clinical evidence of fluid overload# generall!
clinical evidence of fluid overload# generall!
manifested %!:
manifested %!:
Congestive s!mtoms
Congestive s!mtoms
)oo diuretics
)oo diuretics
rather than thiaBide't!e
rather than thiaBide't!e
diuretics are t!icall! necessar! to restore
diuretics are t!icall! necessar! to restore
normal volume status in atients Eith "F.
normal volume status in atients Eith "F.
trength trength
of )+idence > ? of )+idence > ?
39 All a4aila.le for oral or <V administration
)oo Diuretics
)oo Diuretics
Agent Agent Initial Dail! Initial Dail!
Dose Dose
Ma& Total Ma& Total
Dail! Dose Dail! Dose
Elimination: Elimination:
(enal I Met. (enal I Met.
Duration of Duration of
Action Action
Furosemide Furosemide G0'/0mg Hd or G0'/0mg Hd or
%id %id
900 mg 900 mg 961('861M 961('861M /'9 hrs /'9 hrs
;umetanide ;umetanide 0.6'7.0 mg Hd 0.6'7.0 mg Hd
or %id or %id
70 mg 70 mg 9G1(38J1M 9G1(38J1M 9'J hrs 9'J hrs
Torsemide Torsemide 70'G0 mg Hd 70'G0 mg Hd G00 mg G00 mg G01('J01M G01('J01M 7G'79 hrs 7G'79 hrs
Ethacr!nic Ethacr!nic
acid acid
G6'60 mg Hd G6'60 mg Hd
or %id or %id
G00 mg G00 mg 9K1('881M 9K1('881M 9 hrs 9 hrs
395 All a4aila.le for oral or <V administration
Potassium'Saring Diuretics
Potassium'Saring Diuretics
Agent Agent Initial Dail! Initial Dail!
Dose Dose
Ma& Total Ma& Total
Dail! Dose Dail! Dose
Elimination Elimination Duration Duration
of Action of Action
Sironolactone Sironolactone 7G.6'G6 mg 7G.6'G6 mg
Hd Hd
60 mg 60 mg Meta%olic Meta%olic /J'KG hrs /J'KG hrs
Elerenone Elerenone G6'60 mg Hd G6'60 mg Hd 700 mg 700 mg (enal# (enal#
Meta%olic Meta%olic
Un?noEn Un?noEn
Amiloride Amiloride 6 mg Hd 6 mg Hd G0 mg G0 mg (enal (enal G/ hrs G/ hrs
Triamterene Triamterene 60'K6 mg 60'K6 mg
%id %id
G00 mg G00 mg Meta%olic Meta%olic K'P hrs K'P hrs
"FSA G070 Practice ,uideline *P.7# P./+
"FSA G070 Practice ,uideline *P.7# P./+
Device Thera!:
Device Thera!:
Proh!lactic ICD Placement
Proh!lactic ICD Placement
Proh!lactic ICD lacement Proh!lactic ICD lacement should %e considered should %e considered in atients in atients
Eith an )4EF Y861 and mild to moderate "F s!mtoms: Eith an )4EF Y861 and mild to moderate "F s!mtoms:
Ischemic etiolog! Ischemic etiolog! trength of )+idence > A trength of )+idence > A
2on'ischemic etiolog! 2on'ischemic etiolog! trength of )+idence > ? trength of )+idence > ?
In atients Eho are undergoing imlantation of a In atients Eho are undergoing imlantation of a
%iventricular acing device# use of a device that rovides %iventricular acing device# use of a device that rovides
defi%rillation defi%rillation should %e considered. should %e considered. trength of )+idence > ? trength of )+idence > ?
Decisions should %e made in light of functional status and Decisions should %e made in light of functional status and
rognosis %ased on severit! of underl!ing "F and comor%id rognosis %ased on severit! of underl!ing "F and comor%id
conditions# ideall! after 8'9 mos. of otimal medical thera!. conditions# ideall! after 8'9 mos. of otimal medical thera!.
trength of )+idence > C trength of )+idence > C
Adapted from:
"FSA G070 Practice ,uideline *P.K+
"FSA G070 Practice ,uideline *P.K+
Device Thera!:
Device Thera!:
;iventricular Pacing
;iventricular Pacing
Sinus rh!thm
Sinus rh!thm
Treatments ma! differ %ased on cardiac disorder. Treatments ma! differ %ased on cardiac disorder.
Evaluation for ischemic disease and induci%le Evaluation for ischemic disease and induci%le
m!ocardial ischemia should %e included. m!ocardial ischemia should %e included.
Echocardiograh! Echocardiograh!
Electrocardiograh! Electrocardiograh!
Stress imaging *via e&ercise or harmacologic means# using Stress imaging *via e&ercise or harmacologic means# using
m!ocardial erfusion or echocardiograhic imaging+ m!ocardial erfusion or echocardiograhic imaging+
Impro%e symptoms, especially congestion and lo--output Impro%e symptoms, especially congestion and lo--output
symptoms symptoms
?ptimi;e chronic oral therapy) minimi;e side effects ?ptimi;e chronic oral therapy) minimi;e side effects
Identify -ho might !enefit from re%asculari;ation Identify -ho might !enefit from re%asculari;ation
Education patients concerning medication and HF self-assessment Education patients concerning medication and HF self-assessment
Consider enrollment in a disease management program Consider enrollment in a disease management program
Strengt# of E$idence % C
HF'A 1232 Practice Guideline (31+E-31+12$ HF'A 1232 Practice Guideline (31+E-31+12$
OvervieE of Treatment Otions for Patients
OvervieE of Treatment Otions for Patients
Eith Acute Decomensated "F
Eith Acute Decomensated "F
Parenteral %asodilators
Parenteral %asodilators
S
S
(nitroglycerin, nitroprusside, nesiritide$
(nitroglycerin, nitroprusside, nesiritide$
Inotropes
Inotropes
S
S
(milrinone or do!utamine$
(milrinone or do!utamine$
E%ee recommendations for stipulations and restrictions6
Predictors of Mortalit! ;ased on
Predictors of Mortalit! ;ased on
Anal!sis of AD"E(E Data%ase
Anal!sis of AD"E(E Data%ase
Classification and Regression (ree (CAR($ analysis of Classification and Regression (ree (CAR($ analysis of
ADHERE data sho-s, ADHERE data sho-s,
(hree %aria!les are the strongest predictors of mortality in (hree %aria!les are the strongest predictors of mortality in
hospitali;ed ADHF patients, hospitali;ed ADHF patients,
B9N P CE mg<d+
%ystolic (lood pressure Q DDF mm$g
%erum creatinine P =6HF mg<d+
B9N P CE mg<d+
%ystolic (lood pressure Q DDF mm$g
%erum creatinine P =6HF mg<d+
0onaro' GC et al6 ;*,* =>>FI=ME#FH=4A>
Evidence';ased Treatment Across the
Evidence';ased Treatment Across the
Continuum of S!stolic )4D and "F
Continuum of S!stolic )4D and "F
Control "olume
-mprove Clinical &utcomes
.iuretics
enal eplacement
TherapyR
.igo/in
4Blocker
*CE-
or *B
*ldosterone
*ntagonist
or *B
Treat esidual %ymptoms
CT
an -C.R
$.SN<-%.NR
R-n selected patients
Heart Failure .anagement
Heart Failure .anagement
Applying the ACCMAHA
Applying the ACCMAHA
Chronic Heart Failure
Chronic Heart Failure
Guidelines
Guidelines
The Core
The Core
O
Basic management
O
Stage C
O
Beta blockers
O
ACE inhibitors
O
ARB
O
Aldosterone blocker
O
Diuretics
O
Digoxin
O
Hydralazine/Nitrate
O
Deices
O
!notro"ic agents
O
Re#ractory H$
O
Stage D
O
%rans"lantation
O
Subgrou"s
O
H$ &ith normal '(E$
The Core
The Core
Congestive "eart
Congestive "eart
Failure
Failure
O%-ectives
O%-ectives
Pathophysiology
Pathophysiology
.edical (herapy
.edical (herapy
De%ice (herapy
De%ice (herapy
@hat is C"FM
@hat is C"FM
2efinition
2efinition
Prevalence Prevalence
Affects nearly E million Americans currently, TE22,222 ne- cases diagnosed each year Affects nearly E million Americans currently, TE22,222 ne- cases diagnosed each year
Cost Cost
Annual direct cost in T32 !illion dollars Annual direct cost in T32 !illion dollars
Effects 3-1C of patient from E2-EN-years-old and 32C of patient o%er the age of IE Effects 3-1C of patient from E2-EN-years-old and 32C of patient o%er the age of IE
FreHuenc! FreHuenc!
It is the most common inpatient diagnosis in the D' for patients o%er 6E years of age It is the most common inpatient diagnosis in the D' for patients o%er 6E years of age
&isits to their family practitioner on a%erage 1-5 times per year &isits to their family practitioner on a%erage 1-5 times per year
,ender ,ender
.enT -omen in those !et-een B2 and IE years of age .enT -omen in those !et-een B2 and IE years of age
(he se#es are eVual o%er IE years of age (he se#es are eVual o%er IE years of age
Pathoh!siolog! of "eart Failure
Pathoh!siolog! of "eart Failure
Hemodynamic .odel
Hemodynamic .odel
7eurohumoral Adaptations
7eurohumoral Adaptations
^
^
dou!le-edged s-ords_
dou!le-edged s-ords_
Renin-Angiotensin-Aldosterone 'ystem
Renin-Angiotensin-Aldosterone 'ystem
Antidiuretic Hormone
Antidiuretic Hormone
Endothelin
Endothelin
"el initiall!
"el initiall!
&asoconstriction
&asoconstriction
Common Common
Idiopathic Idiopathic
(are (are
Anemia Anemia
Hemochromatosis Hemochromatosis
HI& HI&
HyperMHypothyroidism HyperMHypothyroidism
(achyarrhythmias (achyarrhythmias
(o#ins (o#ins
Hypertension Hypertension
EF A B2C EF A B2C
High output
High output
hyperthyroidism hyperthyroidism
i%entricular Failure
i%entricular Failure
.aFor Criteria
.aFor Criteria
Rales Rales
Cardiomegaly Cardiomegaly
.inor Criteria
.inor Criteria
Hepatomegaly Hepatomegaly
>a!oratory &alues
>a!oratory &alues
7P
7P
ElectrocardiogramMECH?
ElectrocardiogramMECH?
Clinical
Clinical
>a!oratory
>a!oratory
Hemodynamic
Hemodynamic
Reduced EF, Increased Pulm Cap 0edge Pressure Reduced EF, Increased Pulm Cap 0edge Pressure
Electrophysiological
Electrophysiological
A-fi!, A-flutter, &entricular ectopy, &-tach A-fi!, A-flutter, &entricular ectopy, &-tach
Classification of "eart Failure: ACC3A"A Stage vs 2F"A Class Classification of "eart Failure: ACC3A"A Stage vs 2F"A Class
Princiles of Treatment
Princiles of Treatment
'ystolic HF
'ystolic HF
Preload
Preload
Afterload
Afterload
Ionotropy
Ionotropy
7eurohumoral
7eurohumoral
acti%ity
acti%ity
ACE-I, eta-!loc"ers,
ACE-I, eta-!loc"ers,
and aldosterone
and aldosterone
antagonist are the
antagonist are the
mainstay of treatment
mainstay of treatment
Treatment of S!stolic "eart
Treatment of S!stolic "eart
Failure
Failure
ACE Inhi!itors-
ACE Inhi!itors-
0or"s to inhi!it the o%er stimulation of the RA' that leads 0or"s to inhi!it the o%er stimulation of the RA' that leads
to myocardial hypertrophy and fi!rosis to myocardial hypertrophy and fi!rosis
Decrease the rate of mor!idity @ mortality in all pts -ith Decrease the rate of mor!idity @ mortality in all pts -ith
systolic heart failure systolic heart failure
-If treating acute HF, can start after P tolerates and -If treating acute HF, can start after P tolerates and
pulmonary edema is relie%ed pulmonary edema is relie%ed
ACE'I
ACE'I
'?>&D-Enalapril '?>&D-Enalapril
12mgMday (B3 mo$ 12mgMday (B3 mo$
C?7'E7'D'-Enalapril C?7'E7'D'-Enalapril
1+E-B2mg (344 days$ %s 1+E-B2mg (344 days$ %s
place!o place!o
Dse in sta!le, chronic disease (start as early Dse in sta!le, chronic disease (start as early
as discharge-I.PAC(-HF$ as discharge-I.PAC(-HF$
.ild asthma -as not a contraindication .ild asthma -as not a contraindication
0or" irrespecti%e of the etiology of the heart 0or" irrespecti%e of the etiology of the heart
failure failure
;eta'
;eta'
%loc?er thera!'Ehich to ic?M
%loc?er thera!'Ehich to ic?M
6 RC(Ps -ith T N,222 pts already ta"ing ACE-I sho-ed a significant reduction in 6 RC(Ps -ith T N,222 pts already ta"ing ACE-I sho-ed a significant reduction in
total mortality and sudden death (77( 1B, and 5E o%er 3-1 years$ regardless of total mortality and sudden death (77( 1B, and 5E o%er 3-1 years$ regardless of
se%erity se%erity
Carvedilol vs. Metorolol *COMET G008+ Carvedilol vs. Metorolol *COMET G008+
80GP tsS carvedilol G6mg %id vs. metorolol 60 80GP tsS carvedilol G6mg %id vs. metorolol 60 mg %id mg %id
Patient -ith 7LHA Classes II-I& Patient -ith 7LHA Classes II-I&
Car%edilol Kgreater reduction in mortality (77(, 34 o%er E years$ and Car%edilol Kgreater reduction in mortality (77(, 34 o%er E years$ and
cardio%ascular mortality (77(, 36 o%er E years$ than metoprolol !ut cardio%ascular mortality (77(, 36 o%er E years$ than metoprolol !ut
hypotension -as greater in car%edilol (3B %s 33 percent$ hypotension -as greater in car%edilol (3B %s 33 percent$
Aldosterone Antagonists
Aldosterone Antagonists
'pironolactone (Aldactone)
'pironolactone (Aldactone) RA>E' RA>E'
3NNN$
3NNN$
Pts 3,665 Class IIIMI&, ACE, >oop,Dig, EF A 5EC Pts 3,665 Class IIIMI&, ACE, >oop,Dig, EF A 5EC
Decreased all cause mortality of 52C, 77([32 Decreased all cause mortality of 52C, 77([32
Eplerenone (Inspra)
Eplerenone (Inspra) EPHE'D' 1225 EPHE'D' 1225
$
$
Pts 6,6B1 asym >& dysfunction, D., or after .I Pts 6,6B1 asym >& dysfunction, D., or after .I
Dec C& mortality of 35C, 77([B5 Dec C& mortality of 35C, 77([B5
7e-er more selecti%e inhi!itor) fe-er side effects 7e-er more selecti%e inhi!itor) fe-er side effects
E#ercise E#ercise
CHA.P K Cardio%ascular Hospital Atherosclerosis .anagement CHA.P K Cardio%ascular Hospital Atherosclerosis .anagement
Program Program
A'A, !eta-!loc"er, 7itrates, ACE-I, 'tatin, E#ercise, 'mo"ing A'A, !eta-!loc"er, 7itrates, ACE-I, 'tatin, E#ercise, 'mo"ing
Cessation, Dietary counseling (use increased !y 42C$ Cessation, Dietary counseling (use increased !y 42C$
Device Thera!
Device Thera!
T6Eyo T6Eyo
CRI CRI
Diastolic D!sfunction
Diastolic D!sfunction
ACE-I-promote regression of left %entricular hypertrophy ACE-I-promote regression of left %entricular hypertrophy
Blocing the .AA" and "ympathetic 8ervous system Blocing the .AA" and "ympathetic 8ervous system
loc"ing se%eral neurohormonal M cyto"ine systems loc"ing se%eral neurohormonal M cyto"ine systems
Enhancing compensatory mechanisms in acute heart Enhancing compensatory mechanisms in acute heart
failure) 7P failure) 7P
Pharmacogenomics Pharmacogenomics
.irections in $eart 0ailure
.irections in $eart 0ailure
Therapy
Therapy
loc"ing the RAA' and 'ympathetic 7er%ous loc"ing the RAA' and 'ympathetic 7er%ous
system system
Blocing several neurohormonal 9 cytoine systems Blocing several neurohormonal 9 cytoine systems
Enhancing compensatory mechanisms in acute heart Enhancing compensatory mechanisms in acute heart
failure) 7P failure) 7P
Pharmacogenomics Pharmacogenomics
.irections in $eart 0ailure
.irections in $eart 0ailure
Therapy
Therapy
Does inhibition of BNP degradation (when coupled to ACE
inhibition) with omapatrilat improve survival?
Packer et al, Circulation 2002
&"ET9E# *CE<NEP -nhi(itors
&"ET9E# *CE<NEP -nhi(itors
in $eart 0ailure
in $eart 0ailure
&mapatrilat &mapatrilat
Enalapril Enalapril
P=0.187 P=0.187
% Event Free Survival % Event Free Survival
1.0 1.0
0.8 0.8
0.6 0.6
0.4 0.4
0.2 0.2
0.0 0.0
0 0 3 3 6 6 9 9 12 12 15 15 18 18 21 21 24 24
Months Months
Etanercept %urvival %tudy (ENE8*+)
Etanercept %urvival %tudy (ENE8*+)
(n=1500)
Mann et al, HFSA 2002
> C A D= DB => =C =B E= EB C> CC CA F= > C A D= DB => =C =B E= EB C> CC CA F= FB B> BC BA H= HB A> AC AA M= MB FB B> BC BA H= HB A> AC AA M= MB
Event Event4 4free survival G free survival G
8eeks 8eeks
Place(o Place(o
Etanercept Etanercept (i' (i' K ti' K ti'
T D6D> T D6D>
MFG C-# >6MD MFG C-# >6MD4 4D6EE D6EE
P T >6EE P T >6EE
Primary End Primary End- -Point (Death or CHF Hospitalization) Point (Death or CHF Hospitalization)
D>> D>>
A> A>
B> B>
C> C>
=> =>
> >
D>> D>>
A> A>
B> B>
C> C>
=> =>
> >
(n=1500)
Packer et al, ACC Late-Breaking Trials 2002
EN*B+E - L --# (osentan (ET
EN*B+E - L --# (osentan (ET
* *
K ET
K ET
B B
*ntagonist) -
*ntagonist) -
n $eart 0ailure (nTD,BDE)
n $eart 0ailure (nTD,BDE)
A>C A>C BA> BA> BDF BDF FHE FHE FC= FC= F>= F>= EME EME =EA =EA D=E D=E DB DB
> >
A>H A>H H=E H=E BFF BFF BDE BDE FHH FHH FD= FD= EAA EAA ==M ==M DDE DDE DM DM
> >
No6 at isk# No6 at isk#
D>> D>>
M> M>
A> A>
H> H>
B> B>
F> F>
C> C>
E> E>
=> =>
D> D>
> >
> > DE DE =B =B EM EM F= F= BF BF HA HA MD MD D>C D>C DDH DDH DE> DE>
Bosentan Bosentan
Place(o Place(o
+og rank p4value# >6AMAB +og rank p4value# >6AMAB
G of Patients (Event40ree from death<$0 hosp) G of Patients (Event40ree from death<$0 hosp)
Weeks from Weeks from
an!omi"ation an!omi"ation
loc"ing the RAA' and 'ympathetic 7er%ous loc"ing the RAA' and 'ympathetic 7er%ous
system system
loc"ing se%eral neurohormonal M cyto"ine systems loc"ing se%eral neurohormonal M cyto"ine systems
Enhancing compensatory mechanisms in acute heart Enhancing compensatory mechanisms in acute heart
failure& B84 failure& B84
Pharmacogenomics Pharmacogenomics
.irections in $eart 0ailure
.irections in $eart 0ailure
Therapy
Therapy
;amieson and Palade ; Cell Biol DMBCI=E#DFD ;amieson and Palade ; Cell Biol DMBCI=E#DFD
*trial<ventricular stretch *trial<ventricular stretch
receptors link (lood volume receptors link (lood volume
to renal function to renal function
$
.istension of a (alloon catheter in .istension of a (alloon catheter in
atria of dogs resulted in diuresis atria of dogs resulted in diuresis
"
$enry, et al6 (DMFB) $enry, et al6 (DMFB)
$
%ecretory granules discovered in %ecretory granules discovered in
the atria the atria
"
2isch (DMFB) 2isch (DMFB)
"
;amieson and Palade (DMBC) ;amieson and Palade (DMBC)
$
de Bold, et al (DMAD) report de Bold, et al (DMAD) report
natriuresis natriuresis
in rats after in1ection of atrial in rats after in1ection of atrial
e/tracts e/tracts
$
BNP 'as characteri5ed (y amino BNP 'as characteri5ed (y amino
acid seOuence and .N* clones acid seOuence and .N* clones
"
(%udoh, et al6 DMAA and (%udoh, et al6 DMAA and
%eilhamer, et al6 DMAM)6 %eilhamer, et al6 DMAM)6
2atriuretic Petides:
2atriuretic Petides:
The "eart as a Secretor! Organ
The "eart as a Secretor! Organ
Gly Gly
Phe Phe
Ser Ser
Leu Leu
Arg Arg
Arg Arg
Ser Ser
Ser Ser
Cys Cys
HOOC HOOC
Asn Asn
Gly Gly
H H
2 2
N N
7 7
23 23
Arg Arg
Cys Cys
Gly Gly
Leu Leu
Gly Gly
Ser Ser
Gin Gin
Met Met
Asp Asp
Arg Arg
Ile Ile
Gly Gly
Ala Ala
Ser Ser
Phe Phe
Arg Arg
Tyr Tyr
1 1
5 5
10 10
15 15
20 20
25 25
28 28
Ser Ser
Pro Pro
Lys Lys
Met Met
Val Val
Gin Gin
Gly Gly
Ser Ser
Phe Phe
Lys Lys
Gly Gly
Gly Gly
Cys Cys
Arg Arg
Ser Ser
Lys Lys
Met Met
Asp Asp
H H
2 2
N N
10 10
26 26
Arg Arg
Ile Ile
Ser Ser
Ser Ser
Cys Cys
Gly Gly
Leu Leu
Gly Gly
Ser Ser
Val Val
Leu Leu
Arg Arg
Arg Arg
His His
32 32
30 30
25 25
20 20
15 15
5 5
1 1
HOOC HOOC
Gly Gly
Leu Leu
Ser Ser
Lys Lys
Phe Phe
Gly Gly
Leu Leu
Lys Lys
Leu Leu
Gly Gly
Asp Asp
Arg Arg
Ile Ile
H H
2 2
N N
HOOC HOOC
6 6
22 22
Gly Gly
Ser Ser
Cys Cys
Cys Cys
Gly Gly
Leu Leu
Gly Gly
Ser Ser
Met Met
1 1
5 5
10 10
15 15
20 20
$ .iuretic
$ Natriuretic
$ "ascular rela/ation
$ -nhi(ition of **%, %N%
$ *tria
$ %ame actions as *NP
$ -n atria and ventricles
$ +onger D<= life
$ E/cellent marker
$ 9sed as therapy
$ No natriuresis
or diuresis
$ Potent vasodilator
ANP
BNP
CNP
.
i
u
r
e
t
i
c
.
i
u
r
e
t
i
c
n
a
t
r
i
u
r
e
t
i
c
n
a
t
r
i
u
r
e
t
i
c
Family of Natriuretic Peptides
Gly Gly
Phe Phe
Ser Ser
Leu Leu
Arg Arg
Arg Arg
Ser Ser
Ser Ser
Cys Cys
HOOC HOOC
Asn Asn
Gly Gly
H H
2 2
N N
7 7
23 23
Arg Arg
Cys Cys
Gly Gly
Leu Leu
Gly Gly
Ser Ser
Gin Gin
Met Met
Asp Asp
Arg Arg
Ile Ile
Gly Gly
Ala Ala
Ser Ser
Phe Phe
Arg Arg
Tyr Tyr
1 1
5 5
10 10
15 15
20 20
25 25
28 28
Ser Ser
Pro Pro
Lys Lys
Met Met
Val Val
Gin Gin
Gly Gly
Ser Ser
Phe Phe
Lys Lys
Gly Gly
Gly Gly
Cys Cys
Arg Arg
Ser Ser
Lys Lys
Met Met
Asp Asp
H H
2 2
N N
10 10
26 26
Arg Arg
Ile Ile
Ser Ser
Ser Ser
Cys Cys
Gly Gly
Leu Leu
Gly Gly
Ser Ser
Val Val
Leu Leu
Arg Arg
Arg Arg
His His
32 32
30 30
25 25
20 20
15 15
5 5
1 1
HOOC HOOC
Gly Gly
Leu Leu
Ser Ser
Lys Lys
Phe Phe
Gly Gly
Leu Leu
Lys Lys
Leu Leu
Gly Gly
Asp Asp
Arg Arg
Ile Ile
H H
2 2
N N
HOOC HOOC
6 6
22 22
Gly Gly
Ser Ser
Cys Cys
Cys Cys
Gly Gly
Leu Leu
Gly Gly
Ser Ser
Met Met
1 1
5 5
10 10
15 15
20 20
$ .iuretic
$ Natriuretic
$ "ascular rela/ation
$ -nhi(ition of **%, %N%
$ *tria
$ %ame actions as *NP
$ -n atria and ventricles
$ +onger D<= life
$ E/cellent marker
$ 9sed as therapy
$ No natriuresis
or diuresis
$ Potent vasodilator
ANP
BNP CNP
.
i
u
r
e
t
i
c
.
i
u
r
e
t
i
c
n
a
t
r
i
u
r
e
t
i
c
n
a
t
r
i
u
r
e
t
i
c
B-Type Natriuretic Peptide (nesiritide) as Therapy
N N
e e
N N
N N
e e
N N
2
2
$
$
P
P
+
+
G
G
%
%
P
P
G
G
%
%
*
*
%
%
?
?
T
T
+
+
*
*
P
P
2
2
,
,
.
.
-
-
%
%
%
%
%
%
%
%
G
G
+
+
C
C
C
C
2
2
"
"
+
+
$
$
HH
22
NN
11
10 10
70 70
76 76
90 90
100 100
108 108
Cleavage Cleavage
,
,
.
.
-
-
%
%
%
%
%
%
%
%
G
G
+
+
C
C
C
C
2
2
"
"
+
+
$
$
COOH COOH
COOH COOH
pro pro4 4BNP BNP
HH
22
NN
BNP BNP NT NT4 4proBNP proBNP
Biologically -nactive Biologically -nactive Biologically *ctive Biologically *ctive
$
$
P
P
+
+
G
G
%
%
P
P
G
G
%
%
*
*
%
%
?
?
T
T
+
+
*
*
P
P
COOH COOH
11 10 10 70 70 76 76
C
C
0
0
C
C
%
%
P
P
2
2
,
,
"
"
@
@
G
G
%
%
G
G
HH
22
NN
C
C
0
0
C
C
%
%
P
P
2
2
,
,
"
"
@
@
G
G
%
%
G
G
80 80
NT4proBNP# 5o(he >
'ade=2ehrin&
BNP# 2iosite, 2a)er, A..ott,
2e(,man=Co%lter
;'T!e 2atriuretic Petide
;'T!e 2atriuretic Petide
#oung et al, $AMA 2002
BL BL %&m %&m'0m '0m BL BL %&m %&m'0m '0m
30
28
26
24
22
20
18
1hr 2hr 3hr 1hr 2hr 3hr
-1
-4
-7
-10
#*
#*
#*
# #
#*
#*
#*
#*
#
#
Placebo
Nitroglycerin
Nesiritide
Mean Observed Value ( mmHg) Mean Change ( mmHg)
# p < .05 versus placebo
*p < .05 versus nitroglycerin
30
28
26
24
22
20
18
1hr 2hr 3hr 1hr 2hr 3hr
-1
-4
-7
-10
Mean Observed Value ( mmHg) Mean Change ( mmHg)
# p < .05 versus placebo
*p < .05 versus nitroglycerin
Primary End Point: PCWP through 3 Hours Primary End Point: PCWP through 3 Hours
Nesiritide in $eart 0ailure# ",*C
Nesiritide in $eart 0ailure# ",*C
P P
U U
L L
M M
Pulmonary Capillary Wedge Pressure (absolute and change) Pulmonary Capillary Wedge Pressure (absolute and change)
Heart Failure
Heart Failure
Prof Univ Dr Ion C.Tintoiu
Centrul de Cardiologie al Armatei
Universitatea Titu Maiorescu
Ne' .iuretics4 *denosine eceptor
Ne' .iuretics4 *denosine eceptor
,odulators
,odulators
Adenosine Adenosine
1 1
re(eptor anta&onists = re(eptor anta&onists =
loc"ing the RAA' and 'ympathetic 7er%ous loc"ing the RAA' and 'ympathetic 7er%ous
system system
loc"ing se%eral neurohormonal M cyto"ine systems loc"ing se%eral neurohormonal M cyto"ine systems
Enhancing compensatory mechanisms in acute heart Enhancing compensatory mechanisms in acute heart
failure) 7P failure) 7P
Pharmacogenomics Pharmacogenomics
.irections in $eart 0ailure
.irections in $eart 0ailure
Therapy
Therapy
Partial 0atty *cid &/idation (p0&3) -nhi(ition
Partial 0atty *cid &/idation (p0&3) -nhi(ition
<nhi.it fatt) a(id o0idation onl) <nhi.it fatt) a(id o0idation onl)
at hi&h fatt) a(id (on(entrations at hi&h fatt) a(id (on(entrations
6ermit normal fatt) a(id o0idation 6ermit normal fatt) a(id o0idation
rates at ph)siolo&i( fatt) a(id rates at ph)siolo&i( fatt) a(id
(on(entrations (on(entrations
loc"ing the RAA' and 'ympathetic 7er%ous loc"ing the RAA' and 'ympathetic 7er%ous
system system
loc"ing se%eral neurohormonal M cyto"ine systems loc"ing se%eral neurohormonal M cyto"ine systems
Enhancing compensatory mechanisms in acute heart Enhancing compensatory mechanisms in acute heart
failure) 7P failure) 7P
Pharmacogenomics Pharmacogenomics
.irections in $eart 0ailure
.irections in $eart 0ailure
Therapy
Therapy
*nemia in *m(ulatory $eart
*nemia in *m(ulatory $eart
0ailure
0ailure
Tang et al, ACC Presentation 200'
01
701
G01
801
/01
601
Prevalence Incidence (esolution
EF.G6 EF G6'// EF /6Q
throm!osis
throm!osis
Erythropoietin in $eart 0ailure
Erythropoietin in $eart 0ailure
loc"ing the RAA' and 'ympathetic 7er%ous loc"ing the RAA' and 'ympathetic 7er%ous
system system
loc"ing se%eral neurohormonal M cyto"ine systems loc"ing se%eral neurohormonal M cyto"ine systems
Enhancing compensatory mechanisms in acute heart Enhancing compensatory mechanisms in acute heart
failure) 7P failure) 7P
Pharmacogenomics Pharmacogenomics
.irections in $eart 0ailure
.irections in $eart 0ailure
Therapy
Therapy
Pipeline Drug De%elopment in Heart Failure,
Pipeline Drug De%elopment in Heart Failure,
some -inners and losers
some -inners and losers
1ele(ti4e Aldosterone Anta&onists 1ele(ti4e Aldosterone Anta&onists
Is recommended
Is recommended
in atients Eith severe
in atients Eith severe
h!onatremia *serum sodium . 780 mEH3)+
h!onatremia *serum sodium . 780 mEH3)+
Should %e considered
Should %e considered
for all atients
for all atients
demonstrating fluid retention that is difficult to
demonstrating fluid retention that is difficult to
control desite high doses of diuretic and
control desite high doses of diuretic and
sodium restriction.
sodium restriction.
trength of )+idence > trength of )+idence >
C C
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
2onharmacologicC2utrition in Advanced "F
2onharmacologicC2utrition in Advanced "F
It It is recommended is recommended that secific attention %e aid to that secific attention %e aid to
nutritional management of atients Eith advanced "F and nutritional management of atients Eith advanced "F and
unintentional Eeight loss or muscle Easting *cardiac unintentional Eeight loss or muscle Easting *cardiac
cache&ia+. cache&ia+.
Measurement of nitrogen %alance# caloric inta?e# and Measurement of nitrogen %alance# caloric inta?e# and
real%umin ma! %e useful in determining aroriate real%umin ma! %e useful in determining aroriate
nutritional sulementation. nutritional sulementation.
Ana%olic steroids are Ana%olic steroids are not recommended not recommended for cache&ic for cache&ic
atients. atients.
Strengt# of E$idence % C
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
2onharmacologicC4itamins
2onharmacologicC4itamins
Evaluation for secific vitamin or nutrient deficiencies Evaluation for secific vitamin or nutrient deficiencies
is rarel! necessar!. is rarel! necessar!.
trength of )+idence > trength of )+idence >
C C
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
2onharmacologicC2utraceuticals
2onharmacologicC2utraceuticals
Documentation of the t!e and dose of naturoceutical roducts Documentation of the t!e and dose of naturoceutical roducts
utiliBed %! atients Eith "F utiliBed %! atients Eith "F is recommended is recommended. .
trength of )+idence > C trength of )+idence > C
2aturoceutical use is 2aturoceutical use is not recommended not recommended for relief of s!mtomatic "F for relief of s!mtomatic "F
or for the secondar! revention of cardiovascular events. or for the secondar! revention of cardiovascular events.
Patients should %e instructed to avoid using natural or s!nthetic Patients should %e instructed to avoid using natural or s!nthetic
roducts containing ehedra *ma huang+# ehedrine or its roducts containing ehedra *ma huang+# ehedrine or its
meta%olites %ecause of an increased ris? of mortalit! and meta%olites %ecause of an increased ris? of mortalit! and
mor%idit!. mor%idit!.
Products should %e avoided that ma! have significant drug Products should %e avoided that ma! have significant drug
interactions Eith digo&in# vasodilators# %eta %loc?ers# interactions Eith digo&in# vasodilators# %eta %loc?ers#
antiarrh!thmic drugs and anticoagulants. antiarrh!thmic drugs and anticoagulants.
trength of )+idence > ? trength of )+idence > ?
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
2onharmacologicCCPAP
2onharmacologicCCPAP
#ecommendation @.B
#ecommendation @.B
Pharmacologic aids to slee induction ma! %e Pharmacologic aids to slee induction ma! %e
necessar!. necessar!.
Agents that do not ris? h!sical deendence are Agents that do not ris? h!sical deendence are
referred. referred. trength of trength of
)+idence > C )+idence > C
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
2onharmacologicCDeression
2onharmacologicCDeression
It It is recommended is recommended that screening for endogenous or that screening for endogenous or
rolonged reactive deression in atients Eith "F %e rolonged reactive deression in atients Eith "F %e
conducted folloEing diagnosis and at eriodic intervals as conducted folloEing diagnosis and at eriodic intervals as
clinicall! indicated. clinicall! indicated.
For harmacologic treatment# selective serotonin recetor For harmacologic treatment# selective serotonin recetor
uta?e inhi%itors *SS(Is+ are referred over tric!clic uta?e inhi%itors *SS(Is+ are referred over tric!clic
antideressants# %ecause the latter have the otential to antideressants# %ecause the latter have the otential to
cause ventricular arrh!thmias# %ut the otential for drug cause ventricular arrh!thmias# %ut the otential for drug
interactions should %e considered. interactions should %e considered.
trength of )+idence > ? trength of )+idence > ?
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
2onharmacologicCStress
2onharmacologicCStress
#ecommendation @.%%
#ecommendation @.%%
It
It
is recommended
is recommended
that treatment otions for
that treatment otions for
se&ual d!sfunction %e discussed oenl! Eith %oth
se&ual d!sfunction %e discussed oenl! Eith %oth
male and female atients Eith "F.
male and female atients Eith "F.
These agents are These agents are not recommended not recommended in atients in atients
ta?ing nitrate rearations. ta?ing nitrate rearations.
trength of trength of
)+idence > C )+idence > C
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
2onharmacologicCSmo?ing D Alcohol
2onharmacologicCSmo?ing D Alcohol
It It is recommended is recommended that atients Eith "F %e advised to that atients Eith "F %e advised to
sto smo?ing and to limit alcohol consumtion to Y G sto smo?ing and to limit alcohol consumtion to Y G
standard drin?s er da! in men or Y 7 standard drin? standard drin?s er da! in men or Y 7 standard drin?
er da! in Eomen. er da! in Eomen.
Patients susected of using illicit drugs should %e Patients susected of using illicit drugs should %e
counseled to discontinue such use. counseled to discontinue such use.
trength of )+idence > ? trength of )+idence > ?
Diagnosis of heart failure
Diagnosis of heart failure
ECG 31 leads
ECG 31 leads
Chest H-ray
Chest H-ray
iomar"ers of HF,
iomar"ers of HF,
;2P# ro;2P# C(P#
;2P# ro;2P# C(P#
troonins<
troonins<
Echocardiography (systolicMdiastolic
Echocardiography (systolicMdiastolic
dysfunction, structural heart disease$
dysfunction, structural heart disease$
spiroergometry
spiroergometry
Phisical e&amination
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
2onharmacologicC4accinations
2onharmacologicC4accinations
Endocarditis roh!la&is Endocarditis roh!la&is is not recommended is not recommended %ased on the diagnosis of %ased on the diagnosis of
"F alone. Consistent Eith the A"A recommendation# \roh!la&is should "F alone. Consistent Eith the A"A recommendation# \roh!la&is should
%e given for onl! secific cardiac conditions# associated Eith the highest %e given for onl! secific cardiac conditions# associated Eith the highest
ris? of adverse outcome from endocarditis:$ ris? of adverse outcome from endocarditis:$
congenital heart disease *C"D+$ such as: \unreaired c!anotic C"D# including congenital heart disease *C"D+$ such as: \unreaired c!anotic C"D# including
alliative shunts and conduits alliative shunts and conduits
comletel! reaired congenital heart defect Eith rosthetic material or device# comletel! reaired congenital heart defect Eith rosthetic material or device#
Ehether laced %! surger! or %! catheter intervention# during the first si& months Ehether laced %! surger! or %! catheter intervention# during the first si& months
after the rocedure after the rocedure
reaired C"D Eith residual defects at the site or ad-acent to the site of a rosthetic reaired C"D Eith residual defects at the site or ad-acent to the site of a rosthetic
atch or rosthetic device *Ehich inhi%it endothelialiBation+ atch or rosthetic device *Ehich inhi%it endothelialiBation+
cardiac translantation reciients Eho develo cardiac valvuloath!.$ cardiac translantation reciients Eho develo cardiac valvuloath!.$
Strengt# of E$idence % C
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
2onharmacologicC2SAIDs
2onharmacologicC2SAIDs
#ecommendation @.%@
#ecommendation @.%@
#ecommendation @.%B
#ecommendation @.%B
It
It
is recommended
is recommended
that atients Eith neE or
that atients Eith neE or
recent'onset "F %e assessed for emlo!a%ilit!
recent'onset "F %e assessed for emlo!a%ilit!
folloEing a reasona%le eriod of clinical
folloEing a reasona%le eriod of clinical
sta%iliBation.
sta%iliBation.
It It is recommended is recommended that atients Eith chronic "F Eho that atients Eith chronic "F Eho
currentl! are emlo!ed and Ehose -o% descrition is currentl! are emlo!ed and Ehose -o% descrition is
comati%le Eith their rescri%ed activit! level %e comati%le Eith their rescri%ed activit! level %e
encouraged to remain emlo!ed# even if a temorar! encouraged to remain emlo!ed# even if a temorar!
reduction in hours Eor?ed or tas? erformed is reduction in hours Eor?ed or tas? erformed is
reHuired. reHuired.
(etraining (etraining should %e considered should %e considered and suorted for and suorted for
atients Eith a -o% demanding a level of h!sical atients Eith a -o% demanding a level of h!sical
e&ertion e&ceeding recommended levels. e&ertion e&ceeding recommended levels.
trength of )+idence > trength of )+idence >
? ?
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
2onharmacologicCE&ercise Training
2onharmacologicCE&ercise Training
It is recommended It is recommended that atients Eith "F undergo that atients Eith "F undergo
e&ercise testing to determine suita%ilit! for e&ercise e&ercise testing to determine suita%ilit! for e&ercise
training *atient does not develo significant ischemia training *atient does not develo significant ischemia
or arrh!thmias+. If deemed safe# e&ercise training or arrh!thmias+. If deemed safe# e&ercise training
should %e considered for atients Eith "F in order to: should %e considered for atients Eith "F in order to:
Increase e&ercise duration and intensit! in a Increase e&ercise duration and intensit! in a
suervised setting suervised setting
Promote adherence to a general e&ercise goal of 80 Promote adherence to a general e&ercise goal of 80
minutes of moderate activit!3e&ercise# 6 da!s er Eee? minutes of moderate activit!3e&ercise# 6 da!s er Eee?
Eith Earm u and cool doEn e&ercises Eith Earm u and cool doEn e&ercises
Strengt# of E$idence % '
Drill of the Month
Drill of the Month
De%eloped !y .ichael >indsay
De%eloped !y .ichael >indsay
An Overview of Ventricular
An Overview of Ventricular
Assist Devices
Assist Devices
&
&
Pre Hospital Management
Pre Hospital Management
Student O%-ectives
Student O%-ectives
At the conclusion of this !rill tudents 6ill be
At the conclusion of this !rill tudents 6ill be
able to:
able to:
Define &entricular Assist De%ice (&AD$ and their use in treating Define &entricular Assist De%ice (&AD$ and their use in treating
Heart Failure Heart Failure
Identify types of &entricular Assist De%ices Identify types of &entricular Assist De%ices
E#plain the difference !et-een Pulsatile and 7onpulsatile flo- E#plain the difference !et-een Pulsatile and 7onpulsatile flo-
Identify hemodynamic differences in patients -ith a &AD Identify hemodynamic differences in patients -ith a &AD
Demonstrate ho- to assess a patient -ith a &AD Demonstrate ho- to assess a patient -ith a &AD
Descri!e ho- to treat &AD complications Descri!e ho- to treat &AD complications
Identify &AD resources that can !e utili;ed -hen caring for these Identify &AD resources that can !e utili;ed -hen caring for these
patients+ patients+
"eart Failure
"eart Failure
S
S
Heart failure is a condition -here the heart
Heart failure is a condition -here the heart
cannot pump enough !lood throughout the
cannot pump enough !lood throughout the
!ody+
!ody+
S
S
It de%elops o%er time as the pumping action of
It de%elops o%er time as the pumping action of
the heart gro-s -ea"er+
the heart gro-s -ea"er+
S
S
.ost cases in%ol%e the left side -here the
.ost cases in%ol%e the left side -here the
heart cannot pump enough o#ygen-rich !lood
heart cannot pump enough o#ygen-rich !lood
to the rest of the !ody+
to the rest of the !ody+
S
S
0ith right sided failure, the heart cannot
0ith right sided failure, the heart cannot
effecti%ely pump !lood to the lungs -here the
effecti%ely pump !lood to the lungs -here the
!lood pic"s up o#ygen+
!lood pic"s up o#ygen+
4entricular Assist Device *4AD+
4entricular Assist Device *4AD+
Can !e used for the left (> &AD$, right (R &AD$, or !oth
Can !e used for the left (> &AD$, right (R &AD$, or !oth
%entricles (i &AD$
%entricles (i &AD$
ut, in 1224,
ut, in 1224,
lood enters %ia the inflo- cannula and fills a fle#i!le pumping lood enters %ia the inflo- cannula and fills a fle#i!le pumping
cham!er+ cham!er+
Electric motor or pneumatic (air$ pressure collapses the cham!er Electric motor or pneumatic (air$ pressure collapses the cham!er
and forces !lood into systemic circulation %ia the outflo- cannula+ and forces !lood into systemic circulation %ia the outflo- cannula+
First-generation de%ices (in use since early 3N42s$ First-generation de%ices (in use since early 3N42s$
Patients -ill ha%e a palpa!le pulse and a measura!le !lood pressure+ Patients -ill ha%e a palpa!le pulse and a measura!le !lood pressure+
oth are generated from the &AD output flo-+ oth are generated from the &AD output flo-+
Pulsatile 4AD Ae! Parameters
Pulsatile 4AD Ae! Parameters
Pump Rate,
Pump Rate,
?utput,
?utput,
Impeller (spinning tur!ine-li"e rotor !lade$ propels !lood Impeller (spinning tur!ine-li"e rotor !lade$ propels !lood continuousl! continuousl! for-ard for-ard
into systemic circulation+ into systemic circulation+
A#ial flo-, !lood lea%es impeller !lades in the same direction as it enters (thin" A#ial flo-, !lood lea%es impeller !lades in the same direction as it enters (thin"
fan or !oat motor propeller$+ fan or !oat motor propeller$+
.ost implanted de%ices are >&ADs only .ost implanted de%ices are >&ADs only
Are Vuite and cannot !e heard outside of the patientPs !ody+ Assess &AD status Are Vuite and cannot !e heard outside of the patientPs !ody+ Assess &AD status
!y auscultation o%er the ape# of the >&+ (he &AD should ha%e a continuous, !y auscultation o%er the ape# of the >&+ (he &AD should ha%e a continuous,
smooth humming sound+ smooth humming sound+
(he Patient may ha%e a -ea", irregular, or non-palpa!le pulse (he Patient may ha%e a -ea", irregular, or non-palpa!le pulse
(he Patient may ha%e a narro- pulse pressure and may not !e measura!le -ith (he Patient may ha%e a narro- pulse pressure and may not !e measura!le -ith
automated !lood pressure monitors+ (his is due to the continuous for-ard automated !lood pressure monitors+ (his is due to the continuous for-ard
outflo- from the &AD+ outflo- from the &AD+
(he .ean Arterial Pressure is the "ey in monitoring hemodynamics+ Ideal range (he .ean Arterial Pressure is the "ey in monitoring hemodynamics+ Ideal range
is 6E-N2 mmHg+ is 6E-N2 mmHg+
2on Pulsatile 4AD Ae! Parameters
2on Pulsatile 4AD Ae! Parameters
Flo-,
Flo-,
speed[
speed[
flo-,
flo-,
Qspeed[Qflo-$
Qspeed[Qflo-$
'peed,
'peed,
Po-er,
Po-er,
&aries !y patient
&aries !y patient
Preload-dependent
Preload-dependent
E/G-independent
E/G-independent
Afterload-sensiti%e
Afterload-sensiti%e
Anticoagulated
Anticoagulated
Prone to,
Prone to,
infection
infection
!leeding
!leeding
throm!osisMstro"e
throm!osisMstro"e
mechanical malfunction
mechanical malfunction
Pneumatic, e#ternal(p&AD$ or internal (i&AD$, Pneumatic, e#ternal(p&AD$ or internal (i&AD$, ulsatile ulsatile
pump(s$ pump(s$
'hort- to medium-term use (up to c3-1 years$ 'hort- to medium-term use (up to c3-1 years$
Internally implanted, electric Internally implanted, electric ulsatile ulsatile pump pump
.edium- to long-term therapy (months to years$ .edium- to long-term therapy (months to years$
destination therapy (only FDA-appro%ed D( de%ice$ destination therapy (only FDA-appro%ed D( de%ice$
$eart,ate -- +"*%
$eart,ate -- +"*%
Internally implanted, a#ial-flo- ( Internally implanted, a#ial-flo- (non'ulsatile non'ulsatile$ de%ice $ de%ice
.edium- to long-term therapy (months to years$ .edium- to long-term therapy (months to years$
A#ial-flo- (
A#ial-flo- (
non'ulsatile
non'ulsatile
$ pump
$ pump
electric, intra-%entricular
electric, intra-%entricular
!ridge to transplant
!ridge to transplant
(in%estigational$
(in%estigational$
;arvik =>>> +"*.
;arvik =>>> +"*.
&AD Issues
&AD Issues
Pro(lems<Complications
Pro(lems<Complications
leeding leeding
(hrom!osis (hrom!osis
Infection Infection
sepsis is leading cause of death in long-term &AD support sepsis is leading cause of death in long-term &AD support
'uc"do-n (lo- preload causes a nonpulsatle &AD to collapse the 'uc"do-n (lo- preload causes a nonpulsatle &AD to collapse the
%entricle$ %entricle$
De%ice failureMmalfunction (highly %aria!le !y de%ice type$ De%ice failureMmalfunction (highly %aria!le !y de%ice type$
Hemolysis (the &AD destroys !lood cells$ Hemolysis (the &AD destroys !lood cells$
Pro(lems<Complications
Pro(lems<Complications
Arrhythmias Arrhythmias
A patient can !e in a lethal arrhythmia and !e asymptomatic+ A patient can !e in a lethal arrhythmia and !e asymptomatic+
(reat the patient not the monitor+ (reat the patient not the monitor+
Do not cardio%ertM defi!+ unless the patient is unsta!le -ith the Do not cardio%ertM defi!+ unless the patient is unsta!le -ith the
arrhythmia+ arrhythmia+
Do not initiate chest compressions unless instructed !y a Do not initiate chest compressions unless instructed !y a
physician or &AD coordinator+ Chest compressions can disrupt physician or &AD coordinator+ Chest compressions can disrupt
the implanted eVuipment causing !leeding and death the implanted eVuipment causing !leeding and death
Electrical shoc" from cardio%ertM defi!+ -ill not damage any of Electrical shoc" from cardio%ertM defi!+ -ill not damage any of
the &AD eVuipment the &AD eVuipment
Pro(lems<Complications
Pro(lems<Complications
Hypertension Hypertension
High afterload can limit &AD flo-M output High afterload can limit &AD flo-M output
Do not administer antihypertensi%e medications or nitrates Do not administer antihypertensi%e medications or nitrates
unless instructed !y a physician or &AD Coordinator unless instructed !y a physician or &AD Coordinator
All &ADs are preload dependent+ A loss or reduction in preload All &ADs are preload dependent+ A loss or reduction in preload
-ill compromise &AD function and limit flo-M output -ill compromise &AD function and limit flo-M output
Pro(lems<Complications
Pro(lems<Complications
>i%ing -ith a &AD is difficult to management for a lot of >i%ing -ith a &AD is difficult to management for a lot of
patients+ patients+
A large percentage of patients e#perience symptoms of A large percentage of patients e#perience symptoms of
depression depression
(he e#ternal &AD eVuipment is hea%y and cum!ersome (he e#ternal &AD eVuipment is hea%y and cum!ersome
limiting a patientPs mo!ility and greatly impacting their Vuality limiting a patientPs mo!ility and greatly impacting their Vuality
of life+ of life+
Pro(lems<Complications
Pro(lems<Complications
leeding @ (hrom!osis
leeding @ (hrom!osis
De%ice throm!osis
De%ice throm!osis
typically re%ealed !y increased po-er and signs and typically re%ealed !y increased po-er and signs and
symptoms of hemolysis symptoms of hemolysis
Alarms
Alarms
Ad%isory Alarms
Ad%isory Alarms
Ha;ardous
Ha;ardous
or
or
Critical
Critical
alarms are a loud, continuous,
alarms are a loud, continuous,
shrill sound that ha%e a corresponding
shrill sound that ha%e a corresponding
RED
RED
light
light
that illuminates on the system controller
that illuminates on the system controller
Decrease s!mtoms
Decrease s!mtoms
Decrease mor%idit!
Decrease mor%idit!
Imrove survival
Imrove survival
Cornerstones of Thera!
Cornerstones of Thera!
diuretics
diuretics
digitalis
digitalis
2F"A class II
2F"A class II
2F"A class I4
2F"A class I4
no neurohormonal activation
no neurohormonal activation
decreased hositaliBation
decreased hositaliBation
imroved survival
imroved survival
As!mtomatic Patients
As!mtomatic Patients
Enalopril
Enalopril
'?>&D Pre%ention (rial '?>&D Pre%ention (rial
EF.861 EF.861
hositaliBation hositaliBation
Captopril
Captopril
'A&E, GI''I-5, I'I'-B 'A&E, GI''I-5, I'I'-B
Post MI# EF ./01 Post MI# EF ./01
re'infarction re'infarction
hositaliBation# hositaliBation#
mortalit!# mortalit!#
hositaliBation hositaliBation
C?7'E7'D'-II C?7'E7'D'-II
FC I4 FC I4
s!mtoms# s!mtoms#
hositaliBation hositaliBation
imroved functional class imroved functional class
S!mtomatic Patients
S!mtomatic Patients
>osartan
>osartan
*AT'II inhi%itor+
*AT'II inhi%itor+
E>I(E (rial E>I(E (rial
losartan imroved the survival of elderl! heart failure losartan imroved the survival of elderl! heart failure
atients treated comared Eith catoril thera! atients treated comared Eith catoril thera!
,uidelines to ACE Inhi%itor Thera!
,uidelines to ACE Inhi%itor Thera!
Contraindications
Contraindications
"!er?alemia "!er?alemia
Cough Cough
Angioedema Angioedema
Alternatives
Alternatives
(ecommended for
(ecommended for
atients Eith 2F"A III'I4 and EF .801 or atients Eith 2F"A III'I4 and EF .801 or
ventricular aneur!sm or ver! dilated )4 ventricular aneur!sm or ver! dilated )4
Indicated for
Indicated for
atients Eith heart failure Eho have atrial atients Eith heart failure Eho have atrial
fi%rillation# a rior em%olic eisode# identified fi%rillation# a rior em%olic eisode# identified
intracardiac throm%us# left ventricular aneur!sm# intracardiac throm%us# left ventricular aneur!sm#
throm%ohle%itis# or rolonged %ed rest throm%ohle%itis# or rolonged %ed rest
CHF-'(A(
CHF-'(A(
2F"A II'III atients Eith ischemic
2F"A II'III atients Eith ischemic
cardiom!oath! ' amiodarone had no affect
cardiom!oath! ' amiodarone had no affect
on survival
on survival
GE'ICA
GE'ICA
2F"A III'I4 atients Eith more non'
2F"A III'I4 atients Eith more non'
ischemic cardiom!oath! ' oen la%eled
ischemic cardiom!oath! ' oen la%eled
amiodarone decreased mortalit!
amiodarone decreased mortalit!
AICD
AICD
A&ID A&ID
amiodarone vs imlanta%le defi%rillator amiodarone vs imlanta%le defi%rillator
shoEed the AICD grou had loEer mortalit! shoEed the AICD grou had loEer mortalit!
Physiologic !enefits
Physiologic !enefits
'7 recetors
'7 recetors
Clinical !enefits
Clinical !enefits
HA(
HA(
*
*
'A&E
'A&E
(
(
Survival and 4entricular
Survival and 4entricular
Enlargement
Enlargement
$
$
'%loc?ing thera!
'%loc?ing thera!
'%loc?ing Drugs ' Clinical Trials
'%loc?ing Drugs ' Clinical Trials
.DC
.DC
(
(
Metorolol in Dilated
Metorolol in Dilated
Cardiom!oath!
Cardiom!oath!
$
$
no decrease in mortalit!
no decrease in mortalit!
.?CHA
.?CHA
(
(
Multicenter Oral Carvedilol
Multicenter Oral Carvedilol
"eart Failure Assessment Trial
"eart Failure Assessment Trial
$
$
PRECI'E
PRECI'E
(
(
Prosective (andomiBed Evaluation of
Prosective (andomiBed Evaluation of
Carvedilol on S!mtoms and E&ercise
Carvedilol on S!mtoms and E&ercise
$
$
decrease in s!mtoms
decrease in s!mtoms
Potential !enefit,
Potential !enefit,
Ad%erse effect,
Ad%erse effect,
PRAI'E-3
PRAI'E-3
*Prosective (andomiBed
*Prosective (andomiBed
Amlodiine Survival Evaluation+
Amlodiine Survival Evaluation+
Inclusion Criteria:
Inclusion Criteria:
must first e&clude remedia%le m!ocardial ischemia must first e&clude remedia%le m!ocardial ischemia
heart failure refractor! to otimal medical (& heart failure refractor! to otimal medical (&
left ventricular e-ection fraction .G01 left ventricular e-ection fraction .G01
4O 4O
G G
ma& ma&
7/ m)3?g3min 7/ m)3?g3min
Pro%lems:
Pro%lems:
cardiac outut
cardiac outut
e&ercise tolerance
e&ercise tolerance
natriuresis
natriuresis
neurohormonal activation
neurohormonal activation
Digitalis ' Clinical Trials
Digitalis ' Clinical Trials
DIG
DIG
(Digitalis In%estigation Group$
(Digitalis In%estigation Group$
RADIA7CE
RADIA7CE
(
(
(andomiBed Assessment of the
(andomiBed Assessment of the
effect of Digo&in on Inhi%itors of ACE
effect of Digo&in on Inhi%itors of ACE
$
$
associated Eith
associated Eith
e&ercise
e&ercise
tolerance# and
tolerance# and
in hositaliBation
in hositaliBation
Digitalis ' Clinical Trials
Digitalis ' Clinical Trials
PR?&ED
PR?&ED
*Prosective (andomiBed Stud! of
*Prosective (andomiBed Stud! of
4entricular Function and Efficac! of Digo&in+
4entricular Function and Efficac! of Digo&in+
e&ercise
e&ercise
tolerance and
tolerance and
in hositaliBation
in hositaliBation
Do%utamine
Do%utamine
decrease s!mtoms
decrease s!mtoms
EA.I
EA.I
(E#ercise and Anterior .I$
(E#ercise and Anterior .I$
E>&D
E>&D
(E#ercise in >& Dysfunction$
(E#ercise in >& Dysfunction$
Imrove in survival
Imrove in survival
ACE inhi%itors
ACE inhi%itors
Increased mortalit!
Increased mortalit!
2eutral on survival
2eutral on survival
digitalis
digitalis
Conclusion
Conclusion
Effects of "eart Failure Theraies
Effects of "eart Failure Theraies
Prevention of ischemia
Prevention of ischemia
coronar! revasculariBation
coronar! revasculariBation
anticoagulant thera!
anticoagulant thera!
"emod!namic imrovement
"emod!namic imrovement
The diagnosis of AD"F should %e %ased rimaril! on The diagnosis of AD"F should %e %ased rimaril! on
signs and s!mtoms. signs and s!mtoms. trength of )+idence trength of )+idence
> C > C
@hen the diagnosis is uncertain# determination of ;2P @hen the diagnosis is uncertain# determination of ;2P
or 2T'ro;2P concentration or 2T'ro;2P concentration is recommended is recommended in in
atients %eing evaluated for d!snea Eho have signs atients %eing evaluated for d!snea Eho have signs
and s!mtoms comati%le Eith "F. and s!mtoms comati%le Eith "F. trength of )+idence trength of )+idence
> A > A
The natriuretic etide concentration should not %e The natriuretic etide concentration should not %e
interreted in isolation# %ut in the conte&t of all interreted in isolation# %ut in the conte&t of all
availa%le clinical data %earing on the diagnosis of "F# availa%le clinical data %earing on the diagnosis of "F#
and Eith the ?noEledge of cardiac and non'cardiac and Eith the ?noEledge of cardiac and non'cardiac
factors that can raise or loEer natriuretic etide factors that can raise or loEer natriuretic etide
levels. levels.
3 of 5 3 of 5
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
Acute "FC"osital Admission
Acute "FC"osital Admission
"osital admission
"osital admission
is recommended
is recommended
for atients
for atients
resenting Eith AD"F Ehen the clinical
resenting Eith AD"F Ehen the clinical
circumstances listed in Ta%le 7G.7.a are resent.
circumstances listed in Ta%le 7G.7.a are resent.
Ta%le 7G.7.*a+ Ta%le 7G.7.*a+ "ositaliBation "ositaliBation recommended recommended in the resence of: in the resence of:
Evidence of severel! decomensated "F# including: Evidence of severel! decomensated "F# including:
"!otension "!otension
)ess commonl! reflected %! o&!gen saturation . P01 )ess commonl! reflected %! o&!gen saturation . P01
Including neE onset of raid atrial fi%rillation Including neE onset of raid atrial fi%rillation
Acute coronar! s!ndromes Acute coronar! s!ndromes trength of )+idence > C trength of )+idence > C
5 of 5 5 of 5
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
Acute "FC"osital Admission
Acute "FC"osital Admission
Ta%le 7G.7.*%+ Ta%le 7G.7.*%+ "ositaliBation "ositaliBation should %e considered should %e considered in the resence of: in the resence of:
Signs and s!mtoms of ulmonar! or s!stemic congestion Signs and s!mtoms of ulmonar! or s!stemic congestion
Even in the a%sence of Eeight gain Even in the a%sence of Eeight gain
Pneumonia# ulmonar! em%olus# dia%etic ?etoacidosis# s!mtoms suggestive of Pneumonia# ulmonar! em%olus# dia%etic ?etoacidosis# s!mtoms suggestive of
TIA or stro?e TIA or stro?e
Previousl! undiagnosed "F Eith signs and s!mtoms of s!stemic or Previousl! undiagnosed "F Eith signs and s!mtoms of s!stemic or
ulmonar! congestion ulmonar! congestion
It is recommended
It is recommended
that atients admitted
that atients admitted
Eith AD"F %e treated to achieve the goals
Eith AD"F %e treated to achieve the goals
listed in Ta%le 7G.8.
listed in Ta%le 7G.8.
trength of )+idence > C trength of )+idence > C
1 of 1 1 of 1
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
Acute "FCTreatment ,oals
Acute "FCTreatment ,oals
Ta%le 7G.8 Ta%le 7G.8 Treatment ,oals for Patients Admitted for AD"F Treatment ,oals for Patients Admitted for AD"F
Imrove s!mtoms# eseciall! congestion and loE outut s!mtoms Imrove s!mtoms# eseciall! congestion and loE outut s!mtoms
Identif! and address reciitating factors Identif! and address reciitating factors
Identif! atients Eho might %enefit from revasculariBation or device Identif! atients Eho might %enefit from revasculariBation or device
thera! thera!
Identif! ris? of throm%oem%olism and need for anticoagulant thera! Identif! ris? of throm%oem%olism and need for anticoagulant thera!
Educate atients concerning medications and self assessment of "F Educate atients concerning medications and self assessment of "F
Consider and# Ehere ossi%le# initiate a disease management rogram Consider and# Ehere ossi%le# initiate a disease management rogram
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
Acute "FCPatient Monitoring
Acute "FCPatient Monitoring
It
It
is recommended
is recommended
that the items listed in
that the items listed in
Ta%le 7G./ %e assessed at the stated
Ta%le 7G./ %e assessed at the stated
freHuencies.
freHuencies.
trength of )+idence > C trength of )+idence > C
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
Acute "FCTa%le 7G./. Patient Monitoring^
Acute "FCTa%le 7G./. Patient Monitoring^
FreHuenc! FreHuenc! 4alue 4alue Secifics Secifics
At least dail! At least dail! @eight @eight Determine after voiding in the morning Determine after voiding in the morning
Account for ossi%le increased food inta?e due to imroved Account for ossi%le increased food inta?e due to imroved
aetite aetite
At least dail! At least dail! Fluid inta?e Fluid inta?e
and outut and outut
More than More than
dail! dail!
4ital signs 4ital signs Orthostatic %lood ressure# if indicated Orthostatic %lood ressure# if indicated
O&!gen saturation dail! until sta%le O&!gen saturation dail! until sta%le
At least dail! At least dail! Signs Signs Edema# ascites# ulmonar! rales# heatomegal!# increased Edema# ascites# ulmonar! rales# heatomegal!# increased
-ugular venous ressure# heato-ugular reflu&# liver -ugular venous ressure# heato-ugular reflu&# liver
tenderness tenderness
At least dail! At least dail! S!mtoms S!mtoms Orthonea# aro&!smal nocturnal d!snea or cough# Orthonea# aro&!smal nocturnal d!snea or cough#
nocturnal cough# d!snea# fatigue# lightheadedness nocturnal cough# d!snea# fatigue# lightheadedness
At least dail! At least dail! Electrol!tes Electrol!tes Potassium# sodium Potassium# sodium
At least dail! At least dail! (enal function (enal function ;U2# serum creatinine ;U2# serum creatinine
^All ^All (ecommended (ecommended# Strength of Evidence O C # Strength of Evidence O C
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
Acute "FCFluid Overload and Diuretics
Acute "FCFluid Overload and Diuretics
It is recommended
It is recommended
that atients
that atients
admitted Eith AD"F and evidence of
admitted Eith AD"F and evidence of
fluid overload %e treated initiall! Eith
fluid overload %e treated initiall! Eith
loo diureticsCusuall! given
loo diureticsCusuall! given
intravenousl! rather than orall!.
intravenousl! rather than orall!.
trength of )+idence > ? trength of )+idence > ?
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
Acute "FCDiuretic Dosing
Acute "FCDiuretic Dosing
It
It
is recommended
is recommended
that diuretics %e
that diuretics %e
administered:
administered:
at doses needed to roduce a rate of diuresis sufficient to at doses needed to roduce a rate of diuresis sufficient to
achieve achieve otimal volume status Eith relief of signs and otimal volume status Eith relief of signs and
s!mtoms of congestion s!mtoms of congestion
(edema, ele%ated U&P, dyspnea$ (edema, ele%ated U&P, dyspnea$
Eithout inducing an e&cessivel! raid reduction in: Eithout inducing an e&cessivel! raid reduction in:
intra%ascular %olume, -hich may result in symptomatic intra%ascular %olume, -hich may result in symptomatic
hypotension andMor -orsening renal function hypotension andMor -orsening renal function
or serum electrolytes, -hich may precipitate arrhythmias or or serum electrolytes, -hich may precipitate arrhythmias or
muscle cramps+ muscle cramps+
Strengt# of E$idence % C
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
Acute "FCDiuretics D Assessment
Acute "FCDiuretics D Assessment
trength of )+idence > C trength of )+idence > C
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
Acute "FCDiuretics DMonitoring
Acute "FCDiuretics DMonitoring
Careful o%servation for develoment of a variet! of Careful o%servation for develoment of a variet! of
side effects# including renal d!sfunction# electrol!te side effects# including renal d!sfunction# electrol!te
a%normalities# s!mtomatic h!otension# and gout a%normalities# s!mtomatic h!otension# and gout
is recommended is recommended in atients treated Eith in atients treated Eith
diuretics# eseciall! Ehen used at high doses and in diuretics# eseciall! Ehen used at high doses and in
com%ination. com%ination.
Patients should undergo routine la%orator! studies Patients should undergo routine la%orator! studies
and clinical e&amination as dictated %! their clinical and clinical e&amination as dictated %! their clinical
resonse. resonse.
trength of )+idence > C trength of )+idence > C
1 of 1 1 of 1
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
Acute "FCDiuretic Side Effects
Acute "FCDiuretic Side Effects
It is recommended
It is recommended
that serum otassium and
that serum otassium and
magnesium levels %e monitored at least dail!
magnesium levels %e monitored at least dail!
and maintained in the normal range. More
and maintained in the normal range. More
freHuent monitoring ma! %e necessar! Ehen
freHuent monitoring ma! %e necessar! Ehen
diuresis is raid.
diuresis is raid.
trength of )+idence > trength of )+idence >
C C
@hen congestion fails to imrove in resonse to diuretic @hen congestion fails to imrove in resonse to diuretic
thera!# the folloEing thera!# the folloEing otions otions should %e considered should %e considered: :
Or Or addition of a second t!e of diuretic orall! *metolaBone or addition of a second t!e of diuretic orall! *metolaBone or
sironolactone+ or intravenousl! *chlorothiaBide+. sironolactone+ or intravenousl! *chlorothiaBide+.
Another otion# ultrafiltration# Another otion# ultrafiltration# ma! %e considered ma! %e considered. .
Strengt# of E$idence % C
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
Acute "FCSodium
Acute "FCSodium
Is recommended Is recommended in atients Eith moderate h!onatremia in atients Eith moderate h!onatremia
*serum sodium . 780 mEH3)+ *serum sodium . 780 mEH3)+
Should %e considered Should %e considered to assist in treatment of fluid overload in to assist in treatment of fluid overload in
other atients. other atients. trength of )+idence > C trength of )+idence > C
Is recommended
Is recommended
in the resence of h!o&ia.
in the resence of h!o&ia.
Is not recommended
Is not recommended
in the a%sence of
in the a%sence of
h!o&ia.
h!o&ia.
"trength of Evidence : C "trength of Evidence : C
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
Acute "F''2I4
Acute "F''2I4
In the a%sence of s!mtomatic h!otension# intravenous In the a%sence of s!mtomatic h!otension# intravenous
nitrogl!cerin# nitrorusside or nesiritide nitrogl!cerin# nitrorusside or nesiritide ma! %e ma! %e
considered considered as an addition to diuretic thera! for raid as an addition to diuretic thera! for raid
imrovement of congestive s!mtoms in atients admitted imrovement of congestive s!mtoms in atients admitted
Eith AD"F. Eith AD"F.
trength of )+idence > ? trength of )+idence > ?
FreHuent %lood ressure monitoring FreHuent %lood ressure monitoring is recommended is recommended Eith these Eith these
agents. agents. trength of )+idence > ? trength of )+idence > ?
These agents should %e decreased in dosage or discontinued if These agents should %e decreased in dosage or discontinued if
s!mtomatic h!otension or Eorsening renal function develos. s!mtomatic h!otension or Eorsening renal function develos.
trength of )+idence > ? trength of )+idence > ?
(eintroduction in increasing doses (eintroduction in increasing doses ma! %e considered ma! %e considered once once
s!mtomatic h!otension is resolved. s!mtomatic h!otension is resolved. trength of )+idence > C trength of )+idence > C
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
Acute "FCI4 4asodilators
Acute "FCI4 4asodilators
trength of )+idence > C trength of )+idence > C
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
Acute "FCI4 4asodilators
Acute "FCI4 4asodilators
Intravenous vasodilators
Intravenous vasodilators
ma! %e considered
ma! %e considered
in
in
atients Eith AD"F Eho have ersistent severe
atients Eith AD"F Eho have ersistent severe
"F desite aggressive treatment Eith diuretics
"F desite aggressive treatment Eith diuretics
and standard oral theraies.
and standard oral theraies.
2itrogl!cerine# nesiritide 2itrogl!cerine# nesiritide trength of )+idence > C trength of )+idence > C
3 of 5 3 of 5
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
Acute "FCI4 Inotroes
Acute "FCI4 Inotroes
Intravenous inotroes *milrinone or do%utamine+ Intravenous inotroes *milrinone or do%utamine+ ma! %e ma! %e
considered considered to relieve s!mtoms and imrove end'organ to relieve s!mtoms and imrove end'organ
function in atients Eith advanced "F characteriBed %!: function in atients Eith advanced "F characteriBed %!:
)4 dilation )4 dilation
And And diminished eriheral erfusion or end'organ d!sfunction diminished eriheral erfusion or end'organ d!sfunction
*loE outut s!ndrome+ *loE outut s!ndrome+
"ave marginal s!stolic %lood ressure *.P0 mm "g+# "ave marginal s!stolic %lood ressure *.P0 mm "g+#
"ave s!mtomatic h!otension desite adeHuate filling ressure# "ave s!mtomatic h!otension desite adeHuate filling ressure#
Or Or are unresonsive to# or intolerant of# intravenous vasodilators. are unresonsive to# or intolerant of# intravenous vasodilators.
Strengt# of E$idence % C
1 of 5 1 of 5
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
Acute "FCI4 Inotroes
Acute "FCI4 Inotroes
These agents These agents ma! %e considered ma! %e considered in similar atients Eith in similar atients Eith
evidence of fluid overload if the! resond oorl! to evidence of fluid overload if the! resond oorl! to
intravenous diuretics or manifest diminished or Eorsening intravenous diuretics or manifest diminished or Eorsening
renal function. renal function. trength of )+idence > C trength of )+idence > C
@hen ad-unctive thera! is needed in other atients Eith @hen ad-unctive thera! is needed in other atients Eith
AD"F# administration of vasodilators AD"F# administration of vasodilators should %e considered should %e considered
instead of intravenous inotroes *milrinone or do%utamine+. instead of intravenous inotroes *milrinone or do%utamine+.
trength of )+idence > C trength of )+idence > C
Intravenous inotroes *milrinone or do%utamine+ are Intravenous inotroes *milrinone or do%utamine+ are not not
recommended recommended unless unless left heart filling ressures are ?noEn left heart filling ressures are ?noEn
to %e elevated or cardiac inde& is severel! imaired %ased on to %e elevated or cardiac inde& is severel! imaired %ased on
direct measurement or clear clinical signs. direct measurement or clear clinical signs.
trength of )+idence > C trength of )+idence > C
5 of 5 5 of 5
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
Acute "FCI4 Inotroes
Acute "FCI4 Inotroes
It is recommended
It is recommended
that administration of
that administration of
intravenous inotroes *milrinone or do%utamine+
intravenous inotroes *milrinone or do%utamine+
in the setting of AD"F
in the setting of AD"F
%e accomanied %!
%e accomanied %!
continuous or freHuent %lood ressure monitoring
continuous or freHuent %lood ressure monitoring
and continuous monitoring of cardiac rh!thm.
and continuous monitoring of cardiac rh!thm.
trength of )+idence > trength of )+idence >
C C
trength of )+idence > A trength of )+idence > A
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
Acute "FC"emod!namic Monitoring
Acute "FC"emod!namic Monitoring
Invasive hemod!namic monitoring Invasive hemod!namic monitoring should %e considered should %e considered in a in a
atient: atient:
@hose volume status and cardiac filling ressures are unclear @hose volume status and cardiac filling ressures are unclear
@ho has clinicall! significant h!otension *t!icall! S;P . J0 mm @ho has clinicall! significant h!otension *t!icall! S;P . J0 mm
"g+ or Eorsening renal function during thera! "g+ or Eorsening renal function during thera!
Or Or Eho is %eing considered for cardiac translant and needs Eho is %eing considered for cardiac translant and needs
assessment of degree and reversa%ilit! of ulmon. h!ertension assessment of degree and reversa%ilit! of ulmon. h!ertension
Or Or in Ehom documentation of an adeHuate hemod!namic resonse in Ehom documentation of an adeHuate hemod!namic resonse
to the inotroic agent is necessar! Ehen chronic outatient to the inotroic agent is necessar! Ehen chronic outatient
infusion is %eing considered infusion is %eing considered
Strengt# of E$idence % C
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
Acute "FCEvaluation for Preciitating Factors
Acute "FCEvaluation for Preciitating Factors
It It is recommended is recommended that atients admitted Eith AD"F that atients admitted Eith AD"F
undergo evaluation for the folloEing reciitating factors: undergo evaluation for the folloEing reciitating factors:
Atrial fi%rillation or other arrh!thmias *e.g.# atrial flutter# Atrial fi%rillation or other arrh!thmias *e.g.# atrial flutter#
other S4T or 4T+ other S4T or 4T+
It
It
is recommended
is recommended
that ever! effort %e
that ever! effort %e
made to utiliBe the hosital sta! for
made to utiliBe the hosital sta! for
assessment and imrovement of atient
assessment and imrovement of atient
adherence via atient and famil!
adherence via atient and famil!
education and social suort services.
education and social suort services.
trength of )+idence > ? trength of )+idence > ?
"FSA G070 Practice ,uideline
"FSA G070 Practice ,uideline
Acute "FCDischarge Criteria
Acute "FCDischarge Criteria
It
It
is recommended
is recommended
that criteria in Ta%le
that criteria in Ta%le
7G.K %e met %efore a atient Eith "F is
7G.K %e met %efore a atient Eith "F is
discharged from the hosital.
discharged from the hosital.
Strength of Evidence O C Strength of Evidence O C
Discharge lanning Discharge lanning is recommended is recommended as art of the management of as art of the management of
atients Eith AD"F. Discharge lanning should address the folloEing atients Eith AD"F. Discharge lanning should address the folloEing
issues: issues:
Details regarding medication# dietar! sodium restriction and Details regarding medication# dietar! sodium restriction and
recommended activit! level recommended activit! level
FolloE'u %! hone or clinic visit earl! after discharge to reassess FolloE'u %! hone or clinic visit earl! after discharge to reassess
volume status volume status
Alcohol moderation and smo?ing cessation Alcohol moderation and smo?ing cessation
Monitoring of %od! Eeight# electrol!tes and renal function Monitoring of %od! Eeight# electrol!tes and renal function
Consideration of referral for formal disease management Consideration of referral for formal disease management
Strengt# of E$idence % C
"eart Failure and
"eart Failure and
4ADs
4ADs
;ridges for ;ro?en "earts
;ridges for ;ro?en "earts
Priya Gaiha .D .A
Priya Gaiha .D .A
.ay 16
.ay 16
th th
1232
1232
Dni%ersity of /entuc"y
Dni%ersity of /entuc"y
Grand Rounds
Grand Rounds
O%-ectives
O%-ectives
0hat is the pathophysiology of heart failure` 0hat is the pathophysiology of heart failure`
0hat is the history of mechanical circulatory support` 0hat is the history of mechanical circulatory support`
0hat are the %arious types of %entricular assist de%ices 0hat are the %arious types of %entricular assist de%ices
(&ADs$` (&ADs$`
Ho- and -hen are &ADs used` Ho- and -hen are &ADs used`
0hat is the ne#t generation of &ADs` 0hat is the ne#t generation of &ADs`
Etiologies of cardiac failure
Etiologies of cardiac failure
M!ocarditis M!ocarditis
"!ertension "!ertension
Pathogenesis of "eart Failure
Pathogenesis of "eart Failure
/ann, '. Cir(%lation 1999;1!!;999=1!!#
2F"A classes
2F"A classes
Class Class Patient Symptoms Patient Symptoms
Class I (Mild) Class I (Mild) No limitation of physical activity. Ordinary physical No limitation of physical activity. Ordinary physical
activity does not cause undue fatigue, palpitation, or activity does not cause undue fatigue, palpitation, or
dyspnea (shortness of breath). dyspnea (shortness of breath).
Class II (Mild) Class II (Mild) Slight limitation of physical activity. Comfortable at Slight limitation of physical activity. Comfortable at
rest, but ordinary physical activity results in fatigue, rest, but ordinary physical activity results in fatigue,
palpitation, or dyspnea. palpitation, or dyspnea.
Class III Class III
(Moderate) (Moderate)
Marked limitation of physical activity. Comfortable Marked limitation of physical activity. Comfortable
at rest, but less than ordinary activity causes fatigue, at rest, but less than ordinary activity causes fatigue,
palpitation, or dyspnea. palpitation, or dyspnea.
Class IV (Severe) Class IV (Severe) Unable to carry out any physical activity without Unable to carry out any physical activity without
discomfort. Symptoms of cardiac insufficiency at discomfort. Symptoms of cardiac insufficiency at
rest. If any physical activity is undertaken, rest. If any physical activity is undertaken,
discomfort is increased. discomfort is increased.
www.americanheart.org
5ele4an(e
Otions for Advanced C"F
Otions for Advanced C"F
(ransplant (ZZZZZZ$
(ransplant (ZZZZZZ$
Die(Z$
Die(Z$
Hospice (ZZZ$
Hospice (ZZZ$
:ransplant
_ohn ,i%%on
_ohn ,i%%on
Decrease left ventricular stroke work and Decrease left ventricular stroke work and
myocardial oxygen requirements myocardial oxygen requirements
Most widely used form of mechanical circulatory Most widely used form of mechanical circulatory
support support
Indications for its use include Indications for its use include
Failure to wean from cardiopulmonary bypass Failure to wean from cardiopulmonary bypass
Ele%ated >F(s
Ele%ated >F(s
$agani et al. !nn Thorac Surg %&&&' (&)*+((-,-
Centrifugal ums
Centrifugal ums
E#tracorporeal E#tracorporeal
Centrifugal pump
Centrifugal pump
Percutaneous placement
Percutaneous placement
E#tracorporeal
E#tracorporeal
ridge to transplant
ridge to transplant
Flo-s 6>Mmin
Flo-s 6>Mmin
Circulation+ 122E)331,B54-BB4+
)ong term Device otions
)ong term Device otions
2rid&e to transplant
-eartmate <<
Jar4i, F!!!
CardioHest :A-
-eartmate VV*
Cir(%lation 11F 93;: 3#
:horate(
Thoratec
Thoratec
Pneumatic pump
Pneumatic pump
>&AD, R&AD or
>&AD, R&AD or
!i%entricular support
!i%entricular support
Dura!le
Dura!le
Flo-s I>Mmin
Flo-s I>Mmin
ridge to reco%ery
ridge to reco%ery
ridge to transplant
ridge to transplant
Circulation+ 122E)331,B54-BB4+
"eartmate =4E
"eartmate =4E
A#ial flo-
A#ial flo-
>& support
>& support
Flo-s 32>Mmin
Flo-s 32>Mmin
ridge to transplant
ridge to transplant
Early
Early
leeding leeding
>ate
>ate
Infection Infection
7osocomial 7osocomial
(hrom!oem!olism (hrom!oem!olism
Ad%anced age
Ad%anced age
Independent predictor of poor !ridge to transplant Independent predictor of poor !ridge to transplant
5IC post 52-day >&AD mortality 5IC post 52-day >&AD mortality
Age limit` T6E yo contraindication to transplant Age limit` T6E yo contraindication to transplant
Female
Female
Independent predictor of poor !ridge to transplant Independent predictor of poor !ridge to transplant
>onger -aiting time to transplant due to si;e criteria >onger -aiting time to transplant due to si;e criteria
B-fold increased ris" of early death B-fold increased ris" of early death
Associated -ith end organ failure Associated -ith end organ failure
Increased allograft %asculopathy after transplant Increased allograft %asculopathy after transplant
Increased infections and impaired -ound healing Increased infections and impaired -ound healing
For e%ery 3 mgMd> increase in al!umin, had 3N+1 times increased For e%ery 3 mgMd> increase in al!umin, had 3N+1 times increased
li"elihood for !ridge to transplant li"elihood for !ridge to transplant
JC:1 F!!5:13!;5: 13!F=1311
M!ocardial recover!
M!ocardial recover!
Certain proportion of
Certain proportion of
idiopathic dilated
idiopathic dilated
cardiomyopathy patients
cardiomyopathy patients
ha%e potential for complete
ha%e potential for complete
cardiac reco%ery, 3E-12C
cardiac reco%ery, 3E-12C
Differential includes
Differential includes
Precipitating factors
Precipitating factors
Predisosing Cardiac Diseases
Predisosing Cardiac Diseases
.yocardial infarction
.yocardial infarction
Chronic ischemia
Chronic ischemia
Cardiomyopathy
Cardiomyopathy
Arrhythmias
Arrhythmias
Diastolic dysfunction
Diastolic dysfunction
&al%ular diseases
&al%ular diseases
C? [ '& # HR
C? [ '& # HR
Def,
Def,
4assive stretch of muscle prior to contraction
4assive stretch of muscle prior to contraction
.easurement, '-an-Gan;
.easurement, '-an-Gan;
>&EDP >&EDP
Affected !y
Affected !y
compliance
compliance
>o- compliance [ higher >&EDP d lo-er >&ED& >o- compliance [ higher >&EDP d lo-er >&ED&
Fran"-'tarling right`
Fran"-'tarling right`
Afterload
Afterload
Def,
Def,
Force opposing9stretching muscle
Force opposing9stretching muscle
after
after
contraction begins
contraction begins
.easurement, '&R
.easurement, '&R
'&R
'&R
Def,
Def,
8ormal ability of the muscle to contract
8ormal ability of the muscle to contract
at a given force for a given stretch1
at a given force for a given stretch1
independent
independent
of preload or afterload forces
of preload or afterload forces
In other -ords,
In other -ords,
Anatomically
Anatomically
Physiologically
Physiologically
Functionally
Functionally
'ystolic
'ystolic
K ^canPt pump_
K ^canPt pump_
H(7 H(7
Ischemia Ischemia
Fi!rosis Fi!rosis
Infiltration Infiltration
Diastolic
Diastolic
- ^canPt fill_
- ^canPt fill_
(amponade (amponade
Hypertrophy Hypertrophy
Infiltration Infiltration
Fi!rosis Fi!rosis
Clinical Data
Clinical Data
CHR
CHR
Pulmonary Edema
Pulmonary Edema
Cephali;ation
Cephali;ation
E/G
E/G
Arrhythmias
Arrhythmias
4)A#$ '*(!FFF
4)A#$ '*(!FFF
'ystolic .urmurs
'ystolic .urmurs
.itral Regurg
.itral Regurg
Aortic 'tenosis
Aortic 'tenosis
Diastolic .urmurs
Diastolic .urmurs
.itral 'tenosis
.itral 'tenosis
Aortic Insufficiency
Aortic Insufficiency
S8
S8
, Rapid filling of a diseased %entricle
, Rapid filling of a diseased %entricle
Clinical Data
Clinical Data
>a!oratory Data
>a!oratory Data
Chemistry
Chemistry
7P
7P
Dsed in ER departments the -orld o%er Dsed in ER departments the -orld o%er
Decrease Preload
Decrease Preload
Decrease Afterload
Decrease Afterload
Increase Contractility
Increase Contractility
Increase ?#ygenation
Increase ?#ygenation
Treatment of C"F
Treatment of C"F
.orphine
.orphine
Preload Reduction
Preload Reduction
>oop diuretics
>oop diuretics
7itrates
7itrates
ACEi M AR
ACEi M AR
.orphine
.orphine
"eart
"eart
Failure
Failure
Amanda Ryan, D+?+
Amanda Ryan, D+?+
Cardiology Fello-
Cardiology Fello-
Fe!ruary 3Bth, 1224
Fe!ruary 3Bth, 1224
+earning &(1ectives
Heart failure is B
Heart failure is B
th th
in a list of Vuality of care initiati%es in
in a list of Vuality of care initiati%es in
%ulnera!le older adults
%ulnera!le older adults
Costs of $eart 0ailure
:he ma@orit) of the (osts " appro0imatel) t3o=thirds " are attri.%ta.le to
the mana&ement of episodes of a(%te -+ de(ompensation 9i.e.,
hospitalization;.
Different @a!s to Define "F
Different @a!s to Define "F
2ilated 5congestive6 cardiomyopathy 2ilated 5congestive6 cardiomyopathy is a group of heart is a group of heart
muscle disorders in -hich the %entricles enlarge !ut are not muscle disorders in -hich the %entricles enlarge !ut are not
a!le to pump enough !lood for the !ody*s needs, resulting in a!le to pump enough !lood for the !ody*s needs, resulting in
heart failure+ (E#ample - CAD, myocarditis, Et?H, HI&$ heart failure+ (E#ample - CAD, myocarditis, Et?H, HI&$
Hypertrophic cardiomyopathy Hypertrophic cardiomyopathy includes a group of heart includes a group of heart
disorders in -hich the -alls of the %entricles thic"en disorders in -hich the -alls of the %entricles thic"en
(hypertrophy$ and !ecome stiff, e%en though the -or"load of (hypertrophy$ and !ecome stiff, e%en though the -or"load of
the heart is not increased+ (E#ample K congenital H?C., or the heart is not increased+ (E#ample K congenital H?C., or
acVuired$ acVuired$
.estrictive 5infiltrative6 cardiomyopathy .estrictive 5infiltrative6 cardiomyopathy includes a group of includes a group of
heart disorders in -hich the -alls of the %entricles !ecome heart disorders in -hich the -alls of the %entricles !ecome
stiff, !ut not necessarily thic"ened, and resist normal filling stiff, !ut not necessarily thic"ened, and resist normal filling
-ith !lood !et-een heart!eats+ (E#ample K radiation, -ith !lood !et-een heart!eats+ (E#ample K radiation,
amyloidosis$ amyloidosis$
Different @a!s to Define "F
Different @a!s to Define "F
Hypertension
Hypertension
Dia!etes
Dia!etes
(hyroid pro!lems
(hyroid pro!lems
HI&
HI&
.iastolic $0
!A of patients
. . Isovolumetric relaxation Isovolumetric relaxation, , period occurring bet!een the period occurring bet!een the
end of LV systolic e"ection #$ aortic valve closure% and the end of LV systolic e"ection #$ aortic valve closure% and the
opening of the mitral valve, !hen LV pressure &eeps going its opening of the mitral valve, !hen LV pressure &eeps going its
rapid fall !hile LV volume remains constant. rapid fall !hile LV volume remains constant.
'. '. LV rapid filling LV rapid filling, !hich begins !hen LV pressure falls belo! , !hich begins !hen LV pressure falls belo!
left atrial pressure and the mitral valve opens. During this left atrial pressure and the mitral valve opens. During this
period the blood has an acceleration !hich achieves a maximal period the blood has an acceleration !hich achieves a maximal
velocity, direct related to the magnitude of atrio-ventricular velocity, direct related to the magnitude of atrio-ventricular
pressure, and stops !hen this gradient ends. pressure, and stops !hen this gradient ends.
(. (. diastasis diastasis, !hen left atrial and LV pressures are almost , !hen left atrial and LV pressures are almost
e)ual and LV filling is essentially maintained by the flo! e)ual and LV filling is essentially maintained by the flo!
coming from pulmonary veins * !ith left atrium representing a coming from pulmonary veins * !ith left atrium representing a
passive conduit * !ith an amount depending of LV pressure, passive conduit * !ith an amount depending of LV pressure,
function of LV +compliance+. function of LV +compliance+.
,. ,. atrial systole atrial systole, , !hich corresponds to left atrial contraction !hich corresponds to left atrial contraction
and ends at the mitral valve closure. -his period is mainly and ends at the mitral valve closure. -his period is mainly
influenced by LV compliance, but depends also by the influenced by LV compliance, but depends also by the
pericardial resistance, by the atrial force and by the atrio- pericardial resistance, by the atrial force and by the atrio-
ventricular synchronicity #$ ./0 12 interval%. ventricular synchronicity #$ ./0 12 interval%.
Patient .ifferences
'e(rease salt and 3ater e0(retion from ,idne)s 3hi(h helps maintain
26 .) in(reasin& .lood 4ol%me, this leads to stret(hin& of heartIs
(ham.ers 3hi(h (an impair a.ilit) to (ontra(t
&al%ular regurgitation
&al%ular regurgitation
Pericardial restraint
Pericardial restraint
Cardiac rhythm
Cardiac rhythm
Conduction a!normalities
Conduction a!normalities
R& function
R& function
'mo"ing
'mo"ing
Et?H use
Et?H use
D.
D.
H(7
H(7
Dyslipidemia
Dyslipidemia
(hyroid disorder
(hyroid disorder
Chemotherapy
Chemotherapy
Radiation
Radiation
Cardioto#ic drugs
Cardioto#ic drugs
Fam H# of sudden
Fam H# of sudden
death, CAD, conduction
death, CAD, conduction
pro!lems, HC.
pro!lems, HC.
HI& status
HI& status
Cardiovascular Medical "&
Cardiovascular Medical "&
H# of heart failure
H# of heart failure
Angina
Angina
.I
.I
CAG
CAG
PCI
PCI
Pacema"erMICD
Pacema"erMICD
Em!olic e%ents
Em!olic e%ents
arrhythmias
arrhythmias
C&A
C&A
P&D
P&D
Rheumatic D#
Rheumatic D#
?ther %al%ular h#
?ther %al%ular h#
Congenital
Congenital
Signs and S!mtoms of "F
Signs and S!mtoms of "F
Dyspnea
Dyspnea
P7D
P7D
?rthopnea
?rthopnea
Cough
Cough
E#ercise intolerance
E#ercise intolerance
Edema
Edema
Fatigue
Fatigue
7ausea
7ausea
A!dominal Fullness
A!dominal Fullness
Rales
Rales
'5
'5
Pulmonary edema
Pulmonary edema
U&D
U&D
(achycardia
(achycardia
Cardiomegaly
Cardiomegaly
HepatoFugular refle#
HepatoFugular refle#
Peripheral Edema
Peripheral Edema
Hepatomegaly
Hepatomegaly
"F Diagnosis and Assessment
"F Diagnosis and Assessment
F
F
atigue
atigue
A
A
cti%ity decrease
cti%ity decrease
C
C
ough (especially supine$
ough (especially supine$
E
E
dema
dema
S
S
hortness of !reath
hortness of !reath
2IE0
2IE0
Aroach to the Patient
Aroach to the Patient
@ith "eart Failure
@ith "eart Failure
!
!
iagnose
iagnose
Etiology Etiology
I
I
nitiate
nitiate
-!loc"er -!loc"er
'pirololactone 'pirololactone
Digo#in Digo#in
)
)
ducate
ducate
Diet Diet
E#ercise E#ercise
>ifestyle >ifestyle
$
$
itrate
itrate
?ptimi;e ?ptimi;e
-!loc"er -!loc"er
(herapy of CHF
(herapy of CHF
Clinical Approach to CHF,
Clinical Approach to CHF,
-
Consider etiology
Consider etiology
-
Identify triggers
Identify triggers
-
E#clude ischaemia
E#clude ischaemia
-
General measures
General measures
-
'ymptomatic therapy
'ymptomatic therapy
-
Prognostic therapy
Prognostic therapy
'ee Guide for HF .anagement Chec"-list
'ee Guide for HF .anagement Chec"-list
'ymptoms @ 'igns of HF,
'ymptoms @ 'igns of HF,
8
Fatigue (lo- cardiac out-put$
Fatigue (lo- cardiac out-put$
8
'?
'?
U&P
U&P
8
Rales
Rales
8
'5
'5
8
Edema
Edema
8
Radiologic congestion
Radiologic congestion
8
Cardiomegaly
Cardiomegaly
?!tain CHR to rMo non-cardiac causes e+g+ interstitial lung ?!tain CHR to rMo non-cardiac causes e+g+ interstitial lung
disease @ PPH disease @ PPH
;2P in the Diagnosis of "F
;2P in the Diagnosis of "F
(he role of natriuretic peptides (he role of natriuretic peptides
Produced in atria in response to -all stress Produced in atria in response to -all stress
Produced in %entricles in response to %olume and pressure o%erload Produced in %entricles in response to %olume and pressure o%erload
C7P-central ner%ous system and endothelium C7P-central ner%ous system and endothelium
Produced as prohormones and clea%ed to acti%e molecule Produced as prohormones and clea%ed to acti%e molecule
(A7PM7P$and inacti%e 7( forms (A7PM7P$and inacti%e 7( forms
;2P in the Diagnosis of "F
;2P in the Diagnosis of "F
A7PM7P ele%ated in
A7PM7P ele%ated in
C?PD C?PD
7P study
7P study 5Circ #$$#&*$%( ;*%!;##6 5Circ #$$#&*$%( ;*%!;##6
7P sensiti%ity N2C and specificity I5C for HF 7P sensiti%ity N2C and specificity I5C for HF
;2P Diagnostic Cut Points for C"F
;2P Diagnostic Cut Points for C"F
GACC 211%80B(2,:0BD-CA.
GACC 211%80B(2,:0BD-CA.
7P T B22 pgM> K acute CHF present
7P T B22 pgM> K acute CHF present
7P 322 pgM> K B22 pgM>
7P 322 pgM> K B22 pgM>
8
Diagnostic of CHF -ith
Diagnostic of CHF -ith
RM? pulmonary em!olism, >& dysfunction -ithout acute RM? pulmonary em!olism, >& dysfunction -ithout acute
CHF or cor pulmonale CHF or cor pulmonale
7P A 322 pgM> K N4C negati%e predicti%e accuracy
7P A 322 pgM> K N4C negati%e predicti%e accuracy
Identify triggers
Identify triggers
Acute'sudden onset
Acute'sudden onset
Ischaemia
Ischaemia
Arrhythmia
Arrhythmia
Infection
Infection
Pulmonary em!olism
Pulmonary em!olism
Acute %al%ular
Acute %al%ular
pathology
pathology
Chronic'gradual onset
Chronic'gradual onset
Anemia
Anemia
(hyroto#icosis
(hyroto#icosis
7on-compliance
7on-compliance
Diet
Diet
R# e+g+ 7'AIDPs
R# e+g+ 7'AIDPs
2on'Invasive Evaluation of the "eart Failure
2on'Invasive Evaluation of the "eart Failure
Patient'Imlications of )4 E-ection Fraction
Patient'Imlications of )4 E-ection Fraction
clinical clinical
echo echo
identify triggers
identify triggers
M
M
thyroidMhemochromatosisM
thyroidMhemochromatosisM
pheochromocytoma
pheochromocytoma
8
(o#ins,
(o#ins,
AnthracyclinesMEtohMcocaineMamphetamines
AnthracyclinesMEtohMcocaineMamphetamines
8
&iral C.
&iral C.
8
Idiopathic Dilated C.
Idiopathic Dilated C.
8
?ther,
?ther,
(reatment
(reatment
General .easures
General .easures
General measures,
General measures,
8
Correct triggers and
Correct triggers and
precipitants of acute and
precipitants of acute and
chronic HF
chronic HF
8
>o- sodium diet
>o- sodium diet
8
Fluid restriction
Fluid restriction
8
Regular e#erciseM
Regular e#erciseM
8
Acti%ity HR R#
Acti%ity HR R#
8
(reat ischemia
(reat ischemia
8
Control hypertension
Control hypertension
8
DMC 'mo"ing
DMC 'mo"ing
8
(reat lipid
(reat lipid
a!normalities
a!normalities
8
(reat and control
(reat and control
dia!etes
dia!etes
8
Identify @ R#
Identify @ R#
depression
depression
'ia&nosti( :ests:
CV5>*CN>2N6
*(ho>5NA>/5<:
*tiolo&)>1e4erit)
*dditional Tests
%pecific T/
$Cath
$CA2N
$Val4e 10
'iastoli( -+:
50 (a%se5eferral
1)stoli( -+:
/edi(al10>'e4i(e
<s it -eart +ail%reX
1)mptoms T 1i&ns
Life 1t)le D
6atient *d%(ation
-+ Clini(s +>Q
"F Management Algorithm
"F Management Algorithm
<E"
<E"
Primar! Targets of Treatments
Primar! Targets of Treatments
in C"F
in C"F
Jess%p, N*J/ F!!3
Assess >& Function (echo, gated R7A$
8EF A B2C-systolic dysfunction
8EF B2-EEC-systolicMdiastolic dysfunction
8EF TEEC-diastolic dysfunction
Assess &olume 'tatus
'igns and 'ymptoms of
Fluid Retention
7o 'igns and 'ymptoms
of Fluid Retention
>oop Diuretic
\M- (hia;ide
(titrate to eu%olemic state$
ACE inhi!itorMAR if ACE intolerant
Com!ination R# if HF, hospitali;ation or -!loc"er intolerant
'pironolactone
(7LHA Class III-I& CHFMEFA5ECMCrA122M/AE$
Add Digo#in for
symptom control
'ymptoms Prognosis @ 'ymptoms
-!loc"er (7LHA II-I&$
"eart Failure Theraeutic ,oal
"eart Failure Theraeutic ,oal
Reduce hospitali;ations
Reduce hospitali;ations
-loc"ers -loc"ers
Diuretics ('pironolactone$ Diuretics ('pironolactone$
Digo#in Digo#in
7o Added 'alt 7o Added 'alt 1 gm 7a 1 gm 7a
Acti%ity as (olerated Acti%ity as (olerated Customi;ed E# (raining Customi;ed E# (raining
(ailored R# (ailored R#
Correct Cause( Correct Cause(
Arrhythmias Arrhythmias
Ischemia Ischemia
4ressure =oad 4ressure =oad
Asymptomatic Asymptomatic Mild9Mod Mild9Mod "evere "evere .efractory .efractory
Modified from 3arner!"tevenson1 ACC HF "ummit Modified from 3arner!"tevenson1 ACC HF "ummit
Severit! of "eart Failure
Severit! of "eart Failure
Modes of Death
Modes of Death
/*5<:=-+ 1t%d) Nro%p. ,ANCE+
1999;353:F!!1=!M.
D=G D=G
=CG =CG
BCG BCG
C$0 C$0
&ther &ther
%udden %udden
.eath .eath
n G 1!3 n G 1!3
N?$* -- N?$* --
=BG =BG
DFG DFG
FMG FMG
C$0 C$0
&ther &ther
%udden %udden
.eath .eath
n G 1!3 n G 1!3
N?$* --- N?$* ---
FBG FBG
DDG DDG
EEG EEG
C$0 C$0
&ther &ther
%udden %udden
.eath .eath
n G FM n G FM
N?$* -" N?$* -"
Theraies Provided %! Toda!$s
Theraies Provided %! Toda!$s
Dual'Cham%er ICDs
Dual'Cham%er ICDs
Atrium @
Atrium @
&entricle
&entricle
4
radycardia sensing radycardia sensing
4
radycardia pacing radycardia pacing
Atrium
4
AT3AF tach!arrh!thmia
detection
4
Antitach!cardia acing
4
Cardioversion
4entricle
4
4T3 4F detection
4
Antitach!cardia acing
4
Cardioversion
4
Defi%rillation
Cardiac (es!nchroniBation
Cardiac (es!nchroniBation
Thera! *C(T+
Thera! *C(T+
Atrial-!i%entricular
Atrial-!i%entricular
stimulation
stimulation
Electrical
Electrical
synchroni;ation
synchroni;ation
narro-er WR'
narro-er WR'
.echanical
.echanical
synchroni;ation
synchroni;ation
re%erse remodeling
re%erse remodeling
%tages of $eart 0ailure
At Ris! for (eart Failure)
%T*GE * $igh risk for developing $0
%T*GE B *symptomatic +" dysfunction
(eart Failure)
%T*GE C Past or current symptoms of $0
%T*GE . End4stage $0
Acute heart failure
Acute heart failure
A"F: A"F:
(he rapid onset of symptoms and signs secondary to (he rapid onset of symptoms and signs secondary to
a!normal cardiac function+ a!normal cardiac function+
(reduced C?, tissue hypoperfusion \ congestion, increase in PC0P$ (reduced C?, tissue hypoperfusion \ congestion, increase in PC0P$
7. 7. 0ith or -ithout pre%ious cardiac disease+ 0ith or -ithout pre%ious cardiac disease+
G. G. (he cardiac dysfunction can !e related, (he cardiac dysfunction can !e related,
a$ to systolic or diastolic dysfunction a$ to systolic or diastolic dysfunction
!$ to a!normalities in cardiac rhythm !$ to a!normalities in cardiac rhythm
c$ to preload and afterload mismatch c$ to preload and afterload mismatch
8. 8. ?ften life threatening and reVuires urgent treatment+ ?ften life threatening and reVuires urgent treatment+
The Tas? Force on Acute "eart Failure of the Euroean Societ! of Cardiolog! The Tas? Force on Acute "eart Failure of the Euroean Societ! of Cardiolog!
70&8*. 0*-+9E: (+o' Cardiac &utput)#
.ecreased perfusion of the (rain (confusion)6
kidneys (impaired renal function),
skin (cyanosis) etc6
7
7B*C28*.
0*-+9E:
#
-ncreased
pulmonary
venous pressure,
pulmonary edema
Acute heart failure
Acute heart failure
Epidemiology
Epidemiology
Poor prognosis,
Poor prognosis,
AMI Q S"F
AMI Q S"F
:
:
52C annual mortality
52C annual mortality
APO:
APO:
B2C annual
B2C annual
mortality
mortality
31C in-hospital mortality
31C in-hospital mortality
3+ 3+ CAD, CAD, 62-I2C (particularly in elderly population$ 62-I2C (particularly in elderly population$
1+ 1+ Dilated cardiomyopathy, arrhythmia, congenital or &HD or Dilated cardiomyopathy, arrhythmia, congenital or &HD or
myocarditis, myocarditis, in youmger su!Fects+ in youmger su!Fects+
The Tas? Force on Acute "eart Failure of the Euroean Societ! of Cardiolog! The Tas? Force on Acute "eart Failure of the Euroean Societ! of Cardiolog!
Acute Heart Failure , Classification
Acute Heart Failure , Classification
+
Acute de no%o (ne- onset of AHF in a patient
Acute de no%o (ne- onset of AHF in a patient
-ithout pre%iously "no-n cardiac dysfunction$+
-ithout pre%iously "no-n cardiac dysfunction$+
or
or
+
Acute decompensation of chronic heart failure+
Acute decompensation of chronic heart failure+
The Tas? Force on Acute "eart Failure of the Euroean Societ! of Cardiolog! The Tas? Force on Acute "eart Failure of the Euroean Societ! of Cardiolog!
Can resent itself as:
Can resent itself as:
*PHARMACOLOGICAL !RA!"GI" #
3e! drugs.
1harmacogenetics.
4etabolic modulation.
5mmunomodulation.
*$onp%armacological trategies#
4yocardial repair and regeneration by6
7tem cell89 progenetorcells
-issue engineering
*Gene t%erapy&
*'"VIC" !H"RAP(#
/2-
3.: VAD
*I$!"RV"$!IO$&
New drugs
NEW ENOTROPICS.
AQUARETICS &NATRIURETICS.
ENDOTHELIN ANTAGONISTS.
NEW B-BLOCKERS.
BROMOCRIBTIN.
Adatation in "F'
Adatation in "F'
S!mathetic nervous
S!mathetic nervous
s!stem is activated
s!stem is activated
-eart rate
+or(e of (ontra(tion
'ilatation of (oronar)
arteries
6erif. 4as(%lar resistan(e
5edistri.%tion 9renal .lood
s%ppl);
'ire(t ()toto0i( effe(t
Apoptosis
A(ti4ation of the 5AA1
Adatation'
Adatation'
Activation of the (AAS
Activation of the (AAS
2lood press%re
6erf%sion of the
@%0ta&lom. appar8t%s
1A a(ti4ation
1odi%m and 3ater retention
Vaso(onstri(tion
Aldosterone
A'- 94asopressin;
/)o(ardial h)pertroph)
/)o(ardial fi.rosis
*ndothel d)sf%n(tion
Coa&%lation
renin